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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation describes the developmental influence of Paramyxoviridae 
infection, beta-defensin expression, and adenoviral mediated gene therapy on 
respiratory epithelia in the perinatal lamb model. This dissertation is divided into 5 
chapters that include a General Introduction, three manuscripts that have been 
submitted for publication or published and a General Conclusion. Chapter 1 briefly 
gives details of the dissertation organization along with a general review of human 
Paramyxoviral infection, beta-defensins, adenoviral-mediated gene therapy and their 
relationship to respiratory epithelia. This is followed by a review of lambs as models 
for Paramyxoviral infection, developmental diseases of the respiratory system, beta-
defensin expression and adenoviral mediated gene therapy. Chapter 1 concludes 
with the specific aims of the dissertation. Chapter 2 characterizes the 
clinicopathological features of the respiratory syncytial virus infection in the preterm 
lamb model and demonstrates age-dependent enhancement of infection. Chapter 3 
defines the developmental tissue distribution mRNA expression and peptide of 
sheep beta-defensin-2 during fetal to adult development. Chapter 4 describes the 
clinicopathological effects of adenoviral mediated gene therapy of a beta-defensin 
on concurrent Paramyxoviral infection. Chapter 5 is in the form of a general 
conclusion and ends with suggestions for future study from this work. 
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Overview 
Preterm infants are at increased risk for severe Paramyxoviral infection and 
respiratory disease can result in death (14,158). Deficient innate immunity, in part, 
may predispose preterm infants to infection, since the respiratory epithelia is 
immature and many innate antimicrobial peptides/proteins are developmental^  
regulated (63,105, 206). Suboptimal expression of developmentally-regulated beta-
defensins by epithelia in the preterm infant may sufficiently alter pulmonary innate 
immunity to increase the susceptibility of respiratory epithelia for severe 
Paramyxoviral infection. Furthermore, supplemental expression of a beta-defensin 
using gene therapy could enhance the innate antiviral immunity of the pulmonary 
antimicrobial milieu to minimize susceptibility to severe Paramyxoviral infection. 
Adenoviral-mediated gene therapy has been used in pulmonary research and it has 
a predilection of respiratory epithelia (122,153). The preterm/neonatal lamb was 
chosen as a potential model since lambs are susceptible to Paramyxoviral infection, 
express beta-defensins, are known recipients of adenoviral mediated gene therapy 
and are commonly used to study preterm/perinatal respiratory disease. This work 1) 
characterizes RSV infection in the preterm lamb model, 2) defines the 
developmental distribution and expression of sheep beta-defensin-2 (SBD2) and 3) 
describes the influence human beta-defensin-6 (HBD6) expression by adenoviral 
mediated gene therapy on the clinicopathological features of PIV3 infection. 
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Paramyxoviridae 
The Paramyxoviridae family of viruses is an important source of disease in 
human and veterinary medicine. Classic Paramyxoviridae diseases such as measles 
or rinderpest are feared not only out of respect for their devastation on susceptible 
populations, but in recent times have become prominent in their potential use as 
biological agents in terrorist-like activity (29, 77). Ubiquitous Paramyxoviridae, such 
as respiratory syncytial viruses or parainfluenza viruses, cause widespread seasonal 
morbidity and, in high risk populations, can cause severe disease requiring 
hospitalization with increased risk for mortality (68). Recently, concerns over the 
impact of emerging Paramyxoviridae such as human metapneumovirus or the 
zoonotic Nipah and Hendra viruses further exemplify the clinical diversity and 
significance of this taxonomic group in human and veterinary medicine (19,183). 
Common features of the Paramyxoviridae family include a spherical to 
pleomorphic virion greater than 150nm (88). Virions are composed of an outer lipid 
envelope derived from the host cell's plasma membrane during budding (i.e. 
exocytosis from the cell). The envelope typically contains 2-3 viral encoded 
transmembrane glycoproteins that form projections (peplomers) on the envelope 
surface and are visible by electron microscopy. The envelope surrounds a 
nucleocapsid composed of a single molecule of single stranded, negative sense 
RNA with viral matrix proteins and a viral-encoded polymerase. Virions are readily 
susceptible to inactivation by heat, lipid solvents, ionic and nonionic detergents, 
formaldehyde, ultraviolet light and oxidizing agents. The susceptibility of the virions 
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to detergent action is consistent with the concept of hand washing as a significant 
means to prevent RSV transmission (90). 
The fundamentals of Paramyxoviridae replication are similar among family 
members with minor differences in proteins used for specific roles (e.g. attachment). 
Attachment and fusion of the virion to the host cell is mediated by specific 
transmembrane protein(s). Upon cellular entry, the virion-associated polymerase 
begins to make positive sense mRNA (from the virion's negative sense single strand 
RNA) for subsequent translation by the host cell's translation machinery. The protein 
products include those for synthesis of progeny negative-sense ssRNA and for 
structural use in final virion assembly. Replication of Paramyxoviridae is dependent 
on the presence of viral polymerase and host cell translation machinery, therefore 
the naked viral RNA is not by itself infectious (88, 144). 
The Paramyxoviridae family is sub-classified by numerous morphologic and 
genetic features into two subfamilies: the Paramyxovirinae and Pneumovirinae 
(Table 1). The Paramyxovirinae subfamily is composed of four genera: 
Respiroviruses, Rubulaviruses, Morbilliviruses and the recently proposed 
Henipaviruses (19). The Pneumovirinae subfamily is composed of two genera: 
Pneumoviruses and Metapneumoviruses (88,183). For this dissertation, the viruses 
of interest are respiratory syncytial virus (RSV) and parainfluenza virus-3 (PIV3) 
species. These viral diseases will be characterized in the following pages. 
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Classification and structure 
Respiratory Syncytial Virus (RSV) 
The Pneumovirus genus is composed of three fundamental species: human 
RSV (hRSV), bovine RSV (bRSV) and murine pneumonia virus (33). Ovine and 
caprine strains of RSV have been described but there is a lack of consensus for their 
designation as either a subgroup (strain) of bRSV or as distinct separate species 
(59, 88, 202). 
The RSV genome is comprised often open reading frames that correspond to 
eleven viral proteins products. The specific proteins with their respective size and 
putative function are summarized in Table 2. Two of the major proteins in RSV 
biology are the attachment (G) and fusion (F) proteins and these transmembrane 
glycoproteins are major targets for neutralizing antibodies (201). 
The G protein plays a major role in the attachment of the RSV as 
demonstrated in vitro by anti-G protein antibodies blocking attachment of virions to 
HeLa cells (106). However, the G protein is not essential for viral propagation and 
assembly as deletion of the G protein diminishes, but does not abolish, the capacity 
for replication (33). This suggests an alternative mechanism for cellular entry. The G 
protein is highly glycosylated which may function to mediate the binding of G protein 
to cells for entry. Removal of RSV virion N- and O-linked oligosaccharides by 
glycanases resulted in a 97% reduction in infectivity (99). Furthermore, RSV binding 
is minimal to CHO cells that are glycosylation- and glycosaminoglycans (GAG)-
deficient, suggesting that surface glycosyl groups and GAGs participate in RSV 
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binding (119). Recent m wfm work on Hep2 cells using an L-selectin antagonist 
(TCB1269) prevented RSV binding and suggested L-selectin-like moieties may be 
involved in RSV binding. Further efforts by that group of investigators identified 
annexin II, a plasminogen- and calcium-binding protein, as a binding agent to G 
protein and a putative RSV receptor (118). The extent of G protein glycosylation is 
variable between cells lines. This variable glycosylation, which likely occurs m vfyo, 
in combination with a relatively low (44%) conservation in amino acid sequence are 
believed to provide a significant portion of the antigenic diversity among strains (33). 
While the G protein is classically described as the major mediator for RSV cellular 
attachment, it is evident that additional factors to the G protein are involved and 
further work is needed to fully define their significance. 
The second major RSV protein is the F protein. Compared to the G protein, 
the F protein is more highly conserved among the strains of RSV and thus makes for 
a preferential target in RSV immunoprophylaxis (201). The F protein mediates fusion 
(or penetration) by the enveloped virion to the cell plasma membrane and provides 
cellular entry (33). Binding of host defense factors may modulate the F protein's 
ability for fusion and ensuing viral activity. For example, recent m wfm work suggests 
surfactant protein A binding to the F protein enhances viral replication and host cell 
IL-8 expression while F protein binding by lactoferrin inhibits viral replication and IL-8 
expression (159). Another product of the F protein is the fusion of infected to 
adjacent cells for formation of the characteristic multinucleated "syncytia". Syncytial 
cell formation is mediated in part by the three N-glycan chains of the F protein and 
most of the fusion activity is attributed to the N500-glycan subunit (207). Once in the 
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cell, interaction of the F protein with Rho A, a cellular GTPase involved with actin 
reorganization, facilitates syncytial formation (143). Furthermore, RSV cellular 
infection promotes cytokeratin 17 expression by the host cell via the NF-%6 signaling 
pathway and this protein is localized primarily to cells forming syncytia (44). RSV 
fusion activity and infection may be enhanced by neuraminidase activity to remove 
the sialic acid residues on the virion membrane (13). Neuraminidase activity is not a 
feature of RSV translational products and this opens the door to an interesting 
question concerning potential polymicrobial disease. Would coinfection with RSV 
and neuraminidase-producing viruses (e.g. influenza or parainfluenza virus), 
bacteria (e.g. Pseudomonas or Streptococcus) and fungi (e.g. Cryptococcus or 
Pneumocystis) lead to enhanced RSV disease (13)? Seemingly there is little 
evidence of coinfection with RSV as being clinically relevant, even with secondary 
bacterial involvement (126). 
Parainfluenza vlrus-3 (PIV3) 
Parainfluenza virus-3 belongs to the Respirovirus genus. Representative 
species in this genus include bovine PIV3, human PIV3, human PIV1, Sendai virus 
(murine PIV1) and Simian virus-10. Some ovine isolates of bovine PIV3, a host 
restricted ruminant virus, are serologically distinct suggesting differences, but viral 
taxonomy of these ovine strains thus far remain classified as bovine PIV3 (3, 88). 
The human PIV3 genome comprises six different gene products and their 
respective functions are listed in Table 3. Similar to RSV, PIV3 has two major 
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transmembrane glycoproteins that are targets for neutralizing antibodies in host 
defense, the hemagglutinin neuraminidase (HN) and fusion (F) proteins (68). 
The HN transmembrane glycoprotein is comparable to the G protein of RSV 
in the important function of viral attachment to host cells. For initial interaction, viral 
particles bind to sialic acid-containing receptors on the host cells surface via the HN 
moiety (75). The HN protein then may enhance the fusion function of the F protein 
for increased efficacy of host cell and virion fusion (150). Following viral replication 
and virion packaging, the neuraminidase function of the HN protein cleaves virion-
bound attachments allowing infection of additional cells. (68, 150). 
The PIV3 fusion (F) transmembrane glycoprotein is also analogous in function 
to the RSV F protein as it is important in fusion of the virion with host cells (75). 
Syncytial cell formation can be seen during PIV3 infection but the frequency tends to 
be less numerous than that of RSV infection and this may be due to the dependence 
of F protein on the presence of homotypic HN protein for efficient function (49,150). 
An additional function described for the PIV3 F protein is hemolysis activity but its 
role, if any, in PIV3 pathogenesis in not well characterized (49, 75) 
Pathogenesis and lesions 
RSV 
Transmission of the RSV virus from an infected individual is primarily through 
infected droplets on hands and fomites, or less likely in large aerosol. These infected 
particles then enter the nose or conjunctiva of a susceptible individual (69). 
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Replication of RSV in the nasopharyngeal epithelium is followed 1-3 days later by 
spread to the epithelium of the lower respiratory tract. Necrotizing bronchiolitis with 
cellular necrosis and sloughing, catarrhal exudate and neutrophilic infiltrates in the 
airway lumen leads to partial or complete occlusion of the small airways, these result 
in the characteristic clinical signs of wheezing, atelectasis and hyperinflation. 
Interstitial pneumonia with mononuclear cell (macrophages, lymphocytes, etc.) 
infiltrate is also seen and may represent a latter stage of infection (68). The current 
view of RSV disease in humans is it lacks secondary bacterial pulmonary 
involvement, but interestingly bacterial urinary tract infections are associated with 
severe RSV disease (126, 140, 181). This is in contrast to ruminant RSV or PIV3 
infection, which is thought predispose the animal to secondary bacterial pneumonia 
(3). 
PIV3 
The pathogenesis of PIV3 is similar in to that of RSV. PIV3 is transmitted by 
aerosol or direct contact of infected secretions. The PIV3 virus has a propensity to 
replicate in the upper airway epithelium. The necrosis of the infected airway cells 
can lead to secondary bacterial infection, most commonly in the trachea. In a small 
proportion of individuals (especially seen in high risk groups such as the very young 
or immunocompromised) the PIV3 infection can go to the epithelium of the lower 
respiratory tract and cause necrotizing bronchiolitis and interstitial pneumonia 
leading to hospitalization (155,194). 
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Clinical features 
RSV 
RSV infection is a globally important respiratory disease of infants and 
children. In the United States alone RSV infection is the most common cause of 
respiratory disease leading to hospitalization in children costing an estimated $300 
to $400 million annually in the late 1980's (68, 81). RSV is the most important cause 
of bronchiolitis in children and the incidence of bronchiolitis hospitalization in children 
under 1 year of age increased 2.4 fold from 1980 to 1996 (67, 169). Infection is 
ubiquitous and most children have been infected by 2 years of age (62). Surveillance 
of RSV infection suggests that seasonal outbreaks typically peak in the mid winter 
months of January to February with minimal endemic activity during the rest of the 
year (68). In most people, RSV infection leads to upper respiratory infection that is 
similar to or somewhat worse than a typical cold. However, in specific populations 
RSV infection can lead to more severe manifestations such as croup, apnea, 
bronchiolitis, or pneumonia with an increased risk of hospitalization and mortality. 
High-risk populations include preterm, young or low birth-weight infants, 
immunodeficient individuals, those with cardiac or pulmonary disease and elderly 
adults (6,186). A putative sequela of severe RSV infection is reactive airway 
disease and asthma (147). This association is controversial and some have 
proposed that instead of RSV predisposing to reactive airway disease and asthma, 
that severe RSV infection may act as a marker for those predisposed to these 
diseases (152). 
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There are at least two major strains of hRSV, A and B, with distinct antigenic 
differences present in the G protein (128). Within each strain are various subtypes 
(genotypes). RSV outbreaks are usually characterized by a single strain and subtype 
with subsequent infections by another strain or subtype. This is thought to partially 
explain the apparent susceptibility of recently infected individuals to subsequent 
RSV infection (67). 
PIV3 
PIV3 is an important and ubiquitous cause of seasonal respiratory disease 
typically manifesting in the late spring to early summer (68). Infection in a healthy 
individual is localized primarily to the upper respiratory tract and is often self-limiting 
with coryza and cough as the most common presentation (68,144,155). However, 
PIV3 can cause more serious respiratory disease such as severe laryngotracheitis 
("croupy" cough), bronchiolitis and pneumonia leading to hospitalization and on rare 
occasions, death (75). Risk factors for severe manifestations of parainfluenza virus 
infection include: primarily lung disease (e.g. cystic fibrosis or asthma), the 
immunocompromised (e.g. transplant recipients), young children, and the elderly 
(57, 68, 76). In young children, PIV3 infection is more frequent than other 
parainfluenza viruses with about 15% of PIV3 infections involving the lower 
respiratory tract and of these 0.3% require hospitalization amounting to nearly 
20,000 children hospitalized annually (41, 61) Parainfluenza viruses, along with 
other viruses are increasingly recognized in exacerbation of cystic fibrosis lung 
disease and may predispose to secondary bacterial infection, including 
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Pseudomonas aemg/nosa which is a persistent problem in cystic fibrosis lungs 
(189). Young children and infants with cystic fibrosis are at increased risk for lower 
respiratory tract infections by PIV3 and other community-acquired viruses resulting 
In increased hospitalization rates and chronic lung damage (76,188). 
Treatment and Prevention 
RSV 
Currently, there is no efficacious treatment for severe RSV and in most cases 
supportive treatment includes: bronchodilators, corticosteroids, fluid therapy, antiviral 
agents (e.g. ribavirin) and oxygen management (142). Recent developments include 
a humanized monoclonal antibody (Palivizumab) against the F protein, which can 
prevent severe manifestations of RSV disease that require hospitalization, but it 
does not prevent infection. However, because of the high costs of individual 
treatment the use of Palivizumab is often restricted to high-risk patients (173). A 
recent concern is that RSV mutants have been selected m vAno that resist 
Palivizumab prophylaxis /n wvo, suggesting that this therapy may select for future 
resistant strains of virus analogous to antibiotic therapy in bacteria (205). The use of 
Palivizumab to prevent severe RSV disease is functionally related to the natural 
disease setting where protection from severe RSV disease in the elderly was 
correlated with neutralizing antibody to RSV (186). 
An obvious solution is to make a vaccine against the F protein (or perhaps the 
G protein) for use in the general and high risk populations. This could greatly reduce 
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RSV-associated health costs, increase worker productivity during seasonal 
outbreaks and minimize severe RSV infection in high-risk groups. Unfortunately, 
vaccine development has been slow and cautious since the 1960's in which 
formalin-inactivated RSV vaccines were clinically tested and some of the vaccinates 
developed severe RSV disease following natural exposure (173). While the 
vaccinates had high levels of non-neutralizing and non protective antibodies, it is not 
clear to what extent, if any, the process of formalin inactivation had on the lack of 
neutralizing antibodies (149). The mechanisms responsible for this are ill-defined 
and have contributed to increased research using modified-live or subunit RSV 
vaccines for various subpopulations based on risk and benefit. Modified live 
vaccines are being directed for use in young infants and perhaps the elderly while 
subunit vaccines are being targeted more for high-risk RSV-seropositive children, 
pregnant women and the elderly (149). Some of the modified live-vaccine research 
utilizes as the core virus bovine PIV3, which is attenuated to non pathogenic in 
humans (47). Interestingly, a bovine PIV3 chimeric vaccine expressing human RSV 
G and F proteins offered protection to challenge against human RSV and PIV3 in 
hamsters (70). While there have been multiple RSV vaccine trials in the past 
decade, not a single one is licensed for general use and attempts at future 
government approval may be rigorous in light of previous RSV vaccine problems. 
PIV3 
Treatment for PIV3 infection is usually symptomatic, but more severe 
manifestations such as respiratory compromise due to severe laryngotracheitis 
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require nebulized bronchodilators to increases airway diameter and corticosteroids 
to decrease inflammation. Exposure to humidified or cold air has anecdotally been 
described to alleviate PIV3-associated mucosal edema and to thin secretions, but 
this has not been thoroughly evaluated scientifically. Ribavirin, a guanine analog, 
has activity against PIV3, but is often administered too late in the infection process 
for significant efficacy. It may be of more value for persistent infection sometimes 
seen in immunocompromised individuals (194). 
Currently there is no licensed vaccine for PIV3 in humans. Work on PIV3 
vaccines (both subunit and modified live vaccines) are progressing with one of the 
investigated modified live vaccines strains being bovine PIV3 (194). The bovine 
PIV3 strain is early in development but a modified-live human PIV3 vaccine 
candidate that has promising efficacy will soon be in phase III human trials (47). 
Summary 
Paramyxoviridae such as RSV and PIV3 are important epitheliotropic 
respiratory pathogens, especially for high-risk patients such as preterm infants and 
the elderly. Preterm infants have increased susceptibility to develop severe 
manifestations of RSV and PIV3 infection. Specific prophylactic and treatment 
regimes to RSV and PIV3 are deficient, in part, due to lack of a good animal model 
for study. Furthermore, an animal model that demonstrates age-dependent disease 
similar to preterm infants is lacking. The preterm lamb would be an excellent 
candidate for a Paramyxoviral infection animal model. 
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Beta-Defenslns 
Antimicrobial Peptide/Proteins 
The body's mucosal surfaces such as the respiratory tract are designed with 
an overlapping complex array of immune defense factors that protect the host from a 
constant barrage of exogenous pathogens and disease. One component of this 
innate defense milieu is antimicrobial peptides/proteins. These peptides and proteins 
are increasingly appreciated for relatively inconspicuous, but active role. It is 
amazing an observation of antibacterial activity was made so many years ago. Early 
recognition of this function was made in the early twentieth century when Dr. 
Alexander Fleming made an insightful discovery that respiratory secretions had 
antibacterial activity and he characterized the properties of the product he termed 
"lysozyme" (51, 52). In the past few decades discoveries in the field have highlighted 
how antimicrobial peptide/proteins are ubiquitous in nature. For instance, the 
diversity of the small cationic peptides called "defensins" are evident in their 
taxonomical range from insects (100) to amphibians (204) to mammals (56,167) 
and in their cellular localization from leukocytes (168) to epithelia (42). In recent 
years with the advances in molecular techniques and computational searches, novel 
genes involved in this defense are continually being discovered (166). 
Overview of pulmonary defense 
In the respiratory tract reside multiple levels of anatomic, cellular and 
molecular components that work together for, in part, the purpose of innate host 
defense. A brief overview of this innate system will help establish a foundation for 
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understanding the roles of antimicrobial peptides. The anatomical arrangement of 
the upper respiratory system (e.g. nasal concha) allows for significant particle 
deposition, humidification and warmth of inhaled air for presentation to the abundant 
gas-exchange regions in alveoli. In much of respiratory tract (primarily nasal cavity, 
trachea, bronchi, and bronchioles) ciliated epithelial cells function to remove cellular 
and foreign particulate debris by way of the mucociliary blanket. Alveoli, which lack a 
functional ciliary system, have residential alveolar macrophages that are responsible 
"cleaning" up any particulate matter and cellular debris (117). These anatomic 
structures and specialized cells contribute to the homeostasis and health of the 
respiratory tract. 
Cellular secretions of the respiratory tract provide molecules that participate in 
host defense including mucus (111), surfactant protein A and D (105), lysozyme 
(52), transferrin (192), ficolins (1,120) lactoferrin (180), secretory leukocyte 
proteinase inhibitor (156), alpha-1 antitrypsin (27), secretory IgA (146), 
phospholipase A2 (45), bactericidal permeability inducing protein (BPI, 55), 
cathelicidin (10), anionic peptide (72) and defensins (174) to name a few. While the 
pulmonary system has multiple protective mechanisms for host defense, infectious 
respiratory disease is still a ubiquitous problem with new respiratory diseases 
continually emerging (127,132,170). Alterations in the expression/function of some 
of these innate antimicrobial peptides/proteins have been suggested as predisposing 
factors to disease. Reduced surfactant A and D in the lung decreases bacterial and 
viral clearance and enhances inflammation associated with the disease (105). 
Furthermore, inactivation of beta-defensins may predispose cystic fibrosis patients to 
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chronic lung infection and inflammation (58, 63). Intuitively, the functional loss of just 
one antimicrobial peptide/protein should not seem to be too biologically significant 
given the abundant redundancy of the "antimicrobial soup". However, after further 
examination it appears that the antimicrobial activity of many of these innate 
molecules is enhanced by the presence of other innate molecules. This suggests 
that the functional loss of even one type of innate molecule may confer a 
generalized loss of efficacy to the rest of the "antimicrobial soup" (165). An example 
of this was seen in mice deficient in mouse beta-defensin-1 function as these mice 
had delayed pulmonary clearance of inoculated Haemophilus influenzae (131). Also, 
HBD4 when combined with lysozyme or HBD3 has increased antibacterial activity 
suggesting synergism (58). 
Some scientists have taken the functional role of antimicrobial 
peptides/proteins to the "next step" by focusing on therapeutic intervention of 
disease by enhanced antimicrobial peptide/protein expression or by direct 
supplementation (12,165). For instance, enhanced cathelicidin (LL-37/hCAP-18) 
expression has been suggested as a possible therapy for treatment of lung infection 
in cystic fibrosis patients (12). Also, airway supplementation of SMAP29, a 
cathelicidin of sheep, reduced M. haemo/yf/ca numbers in bronchoalveolar lavage 
and lesions suggesting a potential therapeutic use with minimal pulmonary toxicity 
(24). These and other studies have encouraged entrepreneurial development as 
many pharmaceutical companies are in the process of testing antimicrobial 
peptides/proteins for topical to systemic use (96). 
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Defensins 
Defensins are widespread in nature and can be found in many fauna and flora 
(154). Defensins are a conserved class of antimicrobial peptides characterized by a 
cationic charge, antimicrobial activity and six to eight highly conserved cysteine 
residues that form intramolecular disulfide bonds. There are three families of 
defensins including alpha-, beta- and theta-defensins each characterized by the 
organization of intramolecular disulfide bonds (200). As seen above, antimicrobial 
peptides/proteins are important components of respiratory innate defense. Of these 
many respiratory molecules, much interest has been given to the beta-defensins, in 
part, because of their epithelial expression, regulation, small size and their 
decreased expression/function as a putative factor for increased susceptibility to 
respiratory disease (63,165). Bovine tracheal antimicrobial peptide (TAP) was the 
first mammalian beta-defensin characterized in detail and this was followed by a 
large increase in beta-defensin research (42,43,165). 
Beta-defensin - structure 
Beta-defensins have a conserved structure of six-cysteine residues (generally 
C-X6-C-X4-C-X9-C-X6-C-C) forming C1-C5, C2-C4 and C3-C6 disulfide 
intramolecular bonds with a molecular structure forming three antiparallel beta-
sheets (79, 82,178). In humans, there are at least six defined beta-defensin gene 
products classified human beta-defensins (HBD) 1-6 (9,16, 58, 71,196). However, 
a recent computational search suggests there may be well over thirty putative beta-
defensin genes and expression of many of these gene products are currently being 
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characterized thereby adding to the knowledge of human beta-defensins (151,166). 
Many of these beta-defensins are located in epithelial cells, but in some species 
beta-defensins are also found in leukocytes (167,168). There are some families of 
peptides and proteins that closely resemble beta-defensins in structure and activity. 
HE2/EP2 belong to a family of proteins located exclusively in the testis and 
epididymis that form splice variants during processing that have beta-defensin-like 
structure and antimicrobial activity (53,185). 
Beta-defensin expression 
Over thirty human beta-defensin genes have been found in up to five different 
clusters that are syntenic with mouse beta-defensins suggesting these regions are 
conserved among species (166). Some of these genes, such as HBD1, appear to be 
constitutively regulated while others such as HBD2 are inducible by pathogens or 
microbial products (e.g. lipopolysaccharide), or cellular inflammatory elements such 
as mitogen-activated protein (MAP) kinase or NF-kappa beta (15, 50,114,125, 
138). During beta-defensin gene expression, exon transcripts are spliced together to 
form a primary translational product that is called a pre-pro-peptide (82). At the N 
terminus is the "pre" portion, a highly conserved signal sequence that is important 
for endoplasmic intracellular trafficking and is cleaved before cellular exocytosis 
(130). The "pro" portion is often highly anionic and thought to offset the cationic C 
terminus and may play a role in intracellular trafficking and folding of the C terminus 
portion (96). The pro-peptide is transported extracellularly where the pro portion is 
cleaved to form the active peptide (78). This last point is not as well-defined and 
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some have suggested only the mature peptide is secreted onto the surface (197). 
Further work is needed for understanding beta-defensin processing. 
Beta-defensin - antimicrobial activity 
Beta-defensins have a wide spectrum of antimicrobial activity with efficacy 
against several species of bacteria, fungi, protozoan parasites and viruses (64, 92, 
164, 203). The mechanism(s) for this antimicrobial activity is not clearly defined, but 
a common thought is that there is alteration of the pathogens outer membrane (198). 
Defensins are cationic and are able to interact with pathogens having a negative 
surface membrane charge. Increase in the net-negative charge of SfapAy/ococcus 
aureus membranes by mprF mutation resulted in increased killing by neutrophil 
alpha-defensins (145). This interaction by electrostatic forces is the proposed first 
phase of defensin interaction with a pathogen. The next phase is generally believed 
to involve integration of the defensin's hydrophobic region with the membrane of the 
pathogen and there are three putative models for this interaction. The first is the 
barrel stave model in which defensins form an alpha-helical transmembrane "pores". 
The aggregate channel model differs slightly from the first in that the defensins 
aggregate as clusters within the membrane forming transient membrane pores. The 
carpet model suggests the defensins widely cover and integrate into the membrane 
effectively causing a detergent-like dissolution (96,104). Increasing the cationic 
charge experimentally does not necessarily make defensins more antimicrobial 
since this altered charge effectively increases electrostatic binding to negatively 
charged pathogens, but often decreases defensin integration into the membrane 
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(96). Alterations of the cationic charge, dimer formation or specific amino acid 
substitutions between defensins may correlate with the spectrum of antimicrobial 
activity; however the intramolecular disulfide bonds are not required for antimicrobial 
activity (161,195). The epithelial distribution of many human beta-defensins at 
mucosal surfaces (respiratory, gastrointestinal, urogenital, etc.) and glands make 
them an important first line of defense against pathogens (198). The antimicrobial 
activity of beta-defensins is at very small (nanogram to microgram/milliliter) doses, 
but there is some evidence that at higher doses the host cell cytotoxicity may occur 
(154). The relative lack of toxicity in host cells is thought to be related to the 
comparatively lower anionic residues on the cellular membrane (165). 
Defensin activity against microbial membranes, while popular in the current 
literature, may not explain all of the direct antimicrobial functions of beta-defensins. 
Some have suggested that intracellular effects of defensin expression may be 
surprisingly important for innate defense against organisms (165). For example, a 
standard antiviral concept is that defensin activity is effective against only enveloped 
viruses (i.e. those with outer membranes), however, in an /n yffm gene therapy 
experiment using an adenovirus vector (a non enveloped virus), adenovirus infection 
was inhibited 3-5 fold by HD5 (an alpha-defensin found in intestinal crypts) and 
HBD1 expression (37, 64, 87). Additional evidence that antiviral activity may not be 
due to direct membrane alteration was shown as human alpha-defensin-1 inhibited 
human immunodeficiency virus (HIV) infection after cellular entry of the virus. The 
authors of that study discussed the possibility that defensins alter cell signaling 
pathways to inhibit viral replication (30). While direct effects of defensin mediated 
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membrane damage is important for antimicrobial activity, additional mechanisms 
need to be further elucidated. 
Beta defensins - additional roles 
Beta-defensins have an increasing number of functions that are rapidly 
becoming more clearly defined. In addition to having direct antimicrobial properties, 
beta-defensins are increasingly appreciated for their suggested roles in innate and 
adaptive immune responses and in cell regulation (124,154). 
Chemotaxis 
Recent evidence suggests beta-defensins may function in cellular chemotaxis 
by interacting with the chemokine receptors. Human beta-defensins-1 &-2 are 
ligands for CC-chemokine receptor-6 (CCR6), a surface receptor of CD45RO+ 
memory T cells and bone-marrow derived immature dendritic cells (109,171,199). 
HBD2 has also been shown to function as a chemotactic agent for TNF-alpha 
primed neutrophils and the purported mechanism was again CCR6 interaction (135). 
The CCR6 mechanism is not exclusive as HBD2 can also recruit mast cells via a 
CCR6 independent pathway that likely signals through G protein-phospholipase C 
(134). Interestingly, the concept of defensins signaling as chemokines has furthered 
research which recently discovered some chemokines have antimicrobial-like activity 
(32). As seen in the examples above, beta-defensins can participate in the 
recruitment of cellular inflammation which is important for the advancement of an 
immune response. 
Immune regulation 
Once leukocytes arrive at sites of inflammation defensins may continue to 
influence the inflammatory response. HBD2, an inducible peptide, can cause mast 
cell degranulation (136). Mouse beta-defensin-2 (MBD2) can act as a ligand for toll­
like receptor-4 on dendritic cells resulting in activation and maturation similar to 
binding by LPS. These activated dendric cells expressed Ty1 polarized 
proinflammatory cytokines such as IL-12, IL1 and IL-6 along with chemokines and 
increased surface expression of MHCII and CCR7 molecules (17). Beta-defensin 
binding to an antigen may also regulate the type and magnitude of immune 
response. In a DMA vaccine model, MBD2 was fused to a nonimmunogenic B-cell 
lymphoma epitope (sFv38) and immunized mice had a robust humoral response and 
antitumor immunity (18). Related work showed that the humoral response to 
(ovalbumin) OVA alone versus OVA bound to HBD1 or HBD2 was significantly 
different with the bound beta-defensin causing an increase in the OVA-specific IgG 
levels at twenty one days post immunization (23). A proposed explanation for this 
augmentation of adaptive immunity could be due to enhanced uptake of the antigen-
bound beta-defensin. This along with defensin activation and maturation of the 
dendric cells via CCR6 complex may augment the response (197). 
Epithelial Regulation and Influence of Beta-Defensins 
Additional effects of beta-defensins are present in the resolution of wounds 
and inflammation. The inducible HBD2, but not the constitutive HBD1, had increased 
mRNA and peptide expression during corneal re-epithelialization suggesting that 
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HBD2 may function in 1) an antimicrobial role near a site of injury and/or 2) a role 
modulating cellular proliferation (124). In contrast HBD1 expression is low during 
proliferation of cells but increased at differentiation. Hyper-expression of HBD1 in 
cells causes rapid differentiation suggesting HBD1 is a regulator of cellular 
differentiation (54). 
Summary 
Beta-defensins are a subclass of antimicrobial peptides that are often found 
at epithelial surfaces consistent with their putative role as contributing to the first line 
of defense against environmental pathogens. Reduction in function or expression of 
just one beta-defensin can greatly affect the innate immunity status of the host. 
Expression of several beta-defensins by pulmonary epithelia appears to be 
developmental^  regulated. The immature respiratory epithelia of preterm infants 
may have functionally insufficient beta-defensin expression which predisposes them 
to severe RSV and PIV3 disease. 
Gene Therapy 
Our understanding of what constitutes "disease" and disease processes has 
been progressively defined at the molecular level. Aberrations of normal host gene 
expression have been increasingly shown to play an associative to causative role in 
disease pathogenesis. This corresponds to the frequent news reports heralding 
potential new "heart-attack" to "Alzheimer's disease" genes (74, 93). The basic 
genomic concepts of disease, from predisposition to causation, lead to the ultimate 
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questions of how to functionally restore or alter expression for healthy homeostasis. 
"Gene therapy" can basically be defined as a medical application using molecular 
techniques to alter disease at the level of genes (98). 
Some of the earliest uses of gene therapy directed placement of selected 
genes into target cells as plasmids. Techniques to transfer nucleotide sequences 
included electroporation, microinjection and particle-mediated bombardment, or by 
altering the exterior of nucleotide sequence with calcium ions or cationic lipids to 
enhance transfers across the plasma membrane (98). While these techniques offer 
unlimited size of genes that can be transferred, they have severe limitations in the 
efficiency of cellular uptake, persistence, and gene expression levels. Researchers 
have since expanded into other methods of gene transfer. 
Viruses are by nature excellent vectors for gene therapy in that they routinely 
perform the "basic" elements desired for effective gene therapy - they are able to 
enter the cell carrying genes and allow for transcription/translation of the newly 
introduced genes (179). Viral vectors are often made to carry gene inserts 
(cassettes) by deleting portions of the wild type-viral genome, usually those regions 
associated with virulence, replication and/or toxicity (116). The benefits of using 
viruses for gene therapy are the comparative ease of cellular entry along with the 
ability of generally sustained gene expression, depending on the virus. However, 
there are limitations to using viral vectors including restrictions on the size of 
inserted gene cassettes into the viral genome, immunologic responses to the 
"foreign" virus and potential for disease caused by the attenuated vector virus. Each 
viral class has certain advantages and disadvantages with respective tissue 
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tropisms that must be recognized prior to application. Specific viral groups utilized as 
virus vectors include: oncoretroviruses (e.g. murine leukemia virus), lentiviruses (e.g. 
human immunodeficiency virus), adenoviruses (e.g. human adenovirus-5), adeno-
associated viruses (e.g. adeno-associated virus-2), and herpes viruses (herpes 
simplex virus-1) (98,179). 
In pulmonary diseases, there are many opportunities for gene therapy to have 
a role in therapeutic intervention. Diseases such as cancer, cystic fibrosis, alpha-1-
antitrypsin deficiency and respiratory distress syndrome are prominent examples of 
this potential (60). Cystic fibrosis is a disease due to a primary genetic defect in the 
function of the cystic fibrosis transmembrane conductor (CFTR) gene product on the 
apical portion of epithelial (94). Lack of a functional CFTR results in abnormally thick 
mucus secretions causing disease in the pancreas, liver, respiratory, reproductive 
and gastrointestinal tracts (157) Patients with lung abnormalities have a thick 
respiratory secretions and a predisposition to pulmonary infection including viruses 
and bacteria, most notably persistent Pseudbmonas eemg/nosa (39,189). This 
predisposition to infection of cystic fibrosis patients is believed to be caused by 
dysfunction of the pulmonary innate immune system, in part, defensin inactivation 
(11,12, 63). While most of the gene therapy efforts in cystic fibrosis patients have 
focused on restoring CFTR expression in pulmonary epithelia, additional efforts to 
restore pulmonary host defenses have also been explored (12). These have mainly 
focused on antimicrobial peptide's expression against bacterial infection, whereas 
beta-defensin gene therapy for enhancing antiviral immunity against 
Paramyxoviridae infection is a more novel concept. 
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Adenoviral-mediated gene therapy 
A common viral vector used in pulmonary cystic fibrosis research is the 
adenovirus (122). Part of the appeal of adenovirus vectors is the tropism to epithelia, 
the cellular site associated with CFTR disease. Adenoviruses typically bind to the 
coxsackie-adenovirus receptor (CAR) that is located preferentially on the basolateral 
portion of differentiated epithelia (153). Additionally, the adenovirus may attach to 
various epithelial adhesion molecules (e.g. alphav-betas or alphav-betas integrins) for 
enhanced CAR mediated transfer or bind to phospholipid for epithelial entry during 
surfactant turnover (8,191). 
Adenoviruses used for gene therapy typically have deleted regions of the 
genome in order to minimize viral toxicity and allow room for target gene insertions. 
Some of the early adenoviruses (first generation) had deletions in the E1 and/or E3 
regions of the viral genome (5,116). E1 gene products modulate viral transcription 
and replication, and thus E1 deletion confers a replication deficient virus (28). 
Interestingly, both E1 and E3 gene products were recently shown to have 
immunosuppressive effects, thus E1/E3 deleted vector viruses elicits more of a host 
immune response than the wild type virus (80,160). Host reaction to adenoviral 
vectors include increased IL-8 production in bronchioles along with increased 
intercellular adhesion molecule-1 (ICAM-1) on epithelia which is consistent with the 
increased neutrophilic infiltration typically seen following adenovirus vector 
inoculation (97,133). Additional deletions in the E2 and E4 regions (second or third 
generations) or deletion of the entire coding region (helper-dependent gutted Ad 
vectors) have reduced host immune response with similar transfection efficacy but 
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variable duration (110,116). Cellular localization of adenoviral gene expression is 
often assessed by use of a reporter gene, such the /acZ gene that encodes for beta-
galactosidase (122). Beta-galactosidase exposure to X-gal (4-bromo-5-chloro-3-
indoyl-beta-D-galactopyrosanide) leaves a blue reaction product in tissues and 
differentiation from endogenous mammalian beta-galactosidases is easily discerned 
using slightly alkaline pH (190). 
Summary 
Adenoviruses are common vectors for respiratory gene therapy, in part, 
because of their natural epitheliotropic nature. Adenoviral delivery of antimicrobial 
peptides has been attempted for eliminating persistent bacterial infection but little is 
known concerning viral infection. Adenoviral delivery of a beta-defensin gene could 
enhance the innate pulmonary immunity and reduce the seventy of Paramyxoviral 
infection. 
The Lamb Model 
Currently, there is no well-recognized model for the study of the severe RSV 
or PIV3 disease associated with preterm and young neonatal infants. 
Paramyxoviridae infection research in high risk groups such as preterm infants is 
limited by technical difficulty, practical and ethical concerns (163,184). Study of 
Paramyxoviridae infection in animal models requires comparable clinical disease, 
lesion development, immunity, or other features that relate to the specific aims of the 
experiment (73). 
RSV animal models 
Animal models for study of human RSV (hRSV) pathogenesis and immune 
response include rats (36), mice (139), ferrets (31), guinea pigs (21), hamsters (26), 
lambs (112) and nonhuman primates (121). Infection in the chimpanzee is viewed by 
some to be the most analogous to human disease, however, animal availability is 
limited, few are naive and they require specialized facilities and management 
making this model impractical (33). Mice are often used in models for human 
disease (including RSV) because of the ease of handling and availability of strains 
with specific knockout genes (139). However, hRSV infection in rodents produces 
only mild bronchitis without overt respiratory disease making distinctions about 
severe infection difficult. Related Pneumovirus models include mouse pneumonia 
virus (MPV) in mice and bovine respiratory syncytial virus (BRSV) infection of 
ruminants. MPV does not cause significant disease or lesions in mice and so is not a 
viable model. BRSV is genomically, antigenically and functionally related to human 
RSV and is host-adapted for ruminant infection causing significant clinical pulmonary 
disease and lesions compatible with human RSV infection (33,102, 202). BRSV 
infection in ruminants is recognized as a parallel viral model for human RSV 
infection (73). 
PIV3 animal models 
Animal models for PIV3 infection are not as aggressively pursued as RSV in 
part due to the less severe nature of PIV3 infection in humans and due to some of 
the "overlap" from the RSV research. Animals used for human PIV3 infection 
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research are similar to RSV models and include rats (141), guinea pigs (38), mice 
(182), hamsters (48), and nonhuman primates (46). Analogous viral models for PIV3 
include the bovine PIV3 which infects ruminants (66,103,176) and the Sendai virus 
of mice and rats (175,187). Recently a caviid parainfluenza virus-3 was described in 
guinea pigs; however, clinical signs and lesions were minimal and it does not appear 
to be an applicable model of human PIV3 disease (172). The ovine model of 
(bovine) PIV3 disease results in consistent lesions and is well-recognized (66,103). 
Comparative pulmonary development 
Preterm infants are prone to respiratory distress syndrome and this is a direct 
result of immature respiratory epithelial development and surfactant synthesis (95, 
129). As discussed later in this chapter, pulmonary epithelial development nears 
functional maturity based, in part, on the production of surfactant for lung compliance 
and the ability to breath outside the womb. The corresponding anatomical growth 
continues postnatally with maturation of the alveolar stage of development (2,40). 
However, preterm and young infants that express inflammatory mediators arising 
from common perinatal treatment regimes (mechanical ventilation or oxygen 
therapy) or infection are prone to develop bronchopulmonary dysplasia (BPD, a.k.a. 
chronic lung disease of immaturity) characterized by primarily by alveolar hypoplasia 
with variable fibrosis, smooth muscle hyperplasia and vascular alterations (91). 
Along with surfactant, many antimicrobial peptides/proteins appear to be 
developmental^  regulated. Neonatal infants have "immature" expression of 
developmental^  regulated bactericidal/permeability-increasing protein (BPI) and 
thus are prone to infection (107,108). Expression of HBD1, an epithelium derived 
human beta-defensin, is developmental^  regulated in the lungs (123). Previous work 
on the bovine beta-defensin (tracheal antimicrobial peptide - TAP) showed no mRNA 
expression in 4 or 6 month old fetuses while adult animals had abundant peptide 
suggesting developmental regulation (42,43). In the preterm infant, pulmonary 
antimicrobial peptides/proteins such as beta-defensins may have immature 
expression which could be a risk factor in development of severe Paramyxoviral 
Infection. 
With a lack of consensus for a Paramyxoviral model, numerous animal 
models are utilized for Paramyxoviral infections each with their own advantages and 
disadvantages (26). The lamb model has many appealing features that make them 
an attractive model for use. Moreover, late term fetal and perinatal lambs have 
proven valuable as pulmonary models for the study of surfactant expression and 
regulation (177), ventilation-induced injury (86), congenital diaphragmatic hernia 
(113), chorioamnionitis (7), sleep apnea (112), lung development (40), perinatal 
pulmonary function (35), ontogeny of pulmonary gene expression (22) and persistent 
pulmonary hypertension of the newborn (65). 
Another consideration for animal models of pulmonary disease is that of lung 
development. There are progressive classifications to the stages of anatomical 
development of the lung: embryonic, pseudoglandular, canalicular, saccular and 
alveolar. In humans (gestation = 40 weeks), the alveolar stage of development has 
typically started by 36 weeks of gestation (as early as 30 weeks of gestation) and 
development continues into the postnatal period (101). In sheep (gestation = -148 
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days), alveolar development begins around day 120. At birth, lambs are further 
along in pulmonary development than infants, but both lambs and infants complete 
alveolar development postnatally (2,40). The beginning of alveolar development /n 
ufem corresponds to the appearance and progressive increase of surfactant 
apoproteins and phospholipids in the lung (95,129). Conversely, rodents (term 
-19.5 days) are bom with pulmonary development still in the saccular stage and true 
alveolar development begins postnatally (4, 25). Mice delivered even 24 hours 
before term often do not survive and this corresponds to initial surfactant expression, 
which occurs just prior to birth and continues to increase postnatally for many days 
(34,193). Rodents are a common model in many Paramyxoviridae research labs 
and are valuable tools for study of RSV immunity at the gene level. However, as 
indicated, in many ways the anatomical and physiological development of the human 
lung is more comparable to that of sheep. With the rate of preterm and low 
birthweight babies on the rise, the ovine model could provide novel insights for the 
increased severity of Paramyxoviridae infection in developing preterm and neonatal 
infants (89). 
Sheep beta-defensins 
Two sheep beta-defensins have recently been identified, sheep beta-
defensin-1 and sheep beta-defensin-2 (SBD1 and SBD2, respectively) (83). Original 
efforts described the beta-defensin genes to chromosome 24, but subsequent efforts 
suggests they reside on chromosome 26 which is more equivalent to bovine 
chromosome 27 (84, 85). Bovine chromosome 27 has syntenic loci comparable with 
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human chromosome 8, the location of several human alpha- and beta-defensins 
genes (115,137). Very little is known about SBD1 and SBD2 and much of the 
expected localization and functional roles come from extrapolation of other beta-
defensins. A study of beta-defensin expression (SBD1 and SBD2) in the ovine 
gastrointestinal tract suggested SBD1 was present in all tissues from tongue to 
colon but not in ileum (83). SBD1 mRNA was also present in the trachea, while 
SBD2 mRNA was localized only to the small intestine and colon. Also, SBD1 and 
SBD2 mRNA expression was markedly variable between animals and 
developmental regulation of expression was suggested. SBD2 is not well-
characterized, but sheep SBD2 expression may be a model for innate immunity 
during pulmonary disease. 
Adenovirus gene therapy 
Adenovirus vectors have been used for pulmonary gene therapy in part 
because of the tropism for respiratory epithelia (153). Young lambs have been 
successfully given adenovirus vectors (e.g. human adenovirus-5) for use as a model 
of gene transfer in cystic fibrosis patients (122,148). The use of adenovirus vectors 
in the lambs of this dissertation were partially modeled after these studies. 
Summary 
The lamb is a proven model for late term fetal and perinatal pulmonary 
disease research. Lambs are naturally susceptible to bovine RSV an analogous viral 
model to human RSV infection. Beta-defensins have been identified in sheep, but 
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have not been thoroughly characterized concerning expression and distribution 
during development. Additionally, adenoviral transfection has been successfully 
performed in young lambs. The preterm/neonatal lamb is an excellent candidate 
model for study of developmental influence on respiratory epithelia to 
Paramyxoviridae infection, beta-defensin expression and adenoviral delivery of a 
beta-defensin gene. 
Summary 
Death in the preterm infant is often associated with respiratory disease and 
this same age-group is at increased risk for severe Paramyxoviral disease (14,158). 
In high risk patients, innate immunity may play a critical role in their susceptibility to 
severe Paramyxoviridae infection (158, 206). Developmental regulation of 
pulmonary antimicrobial peptides/proteins such as beta-defensins may play a role in 
this susceptibility. Developmental distribution and expression of SBD2 is not known, 
but developmental regulation of expression has been suggested for the 
gastrointestinal tract (83). Augmentation of beta-defensin expression by gene 
therapy may provide an elevated innate immune status that would alter severity of 
Paramyxoviridae infection. The preterm/perinatal ovine model is appealing for study 
of developmental expression of beta-defensins as well as Paramyxoviridae infection 
and adenoviral gene therapy. 
The specific aims of this dissertation were to: 
1. Characterize the clinicopathological features of RSV infection in 
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preterm lambs 
2. Define the mRNA expression and peptide distribution of sheep beta-
defensin-2 during development. 
3. Characterize adenoviral-mediated beta-defensin expression on the 
clinicopathological features of concurrent parainfluenza virus-3 infection in 
neonatal lambs. 
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Table 1. Representative members of the subfamilies (19,20, 88,175, 
183). 
Subfamily 
fngwmowrinae 
Genus 
Morbillivirus 
#g»*pmvrKS 
fMgwmovêw 
Species 
Moving/woô^wgMza 3; f/wmoM 
/?wam^weMza wntsga 1 & 3; ^ewfa; v&w (AAcime 
parainfluenza virus 1); and Simian virus 10 
v4vM% paramyrovfTwga 2-9; Awman poro/Ti/ZwgMza 
viruses 2 & 4; Menangle virus; Newcastle disease 
virus {avian parainfluenza virus 1); Mapeura virus; 
Mwmps wrws; forcing rw6w/awrm (la ffg^W-
AAcAoocon-Afgxfco vôiw); and AmioM wrwsga 5 & 
41 
Measles virus (Edmonston virus); Canine 
e/wfgmpgr vint?; j&nde/pgjf vôw; fAocmg 
distemper virus (Seal distemper virus); Cetacean 
morM/nww vinw; and 
vôw 
j%7K6"a v;nw and MpaA vôiw 
ZWfne rg^pyafo/y aymcy/W vznw; Aonom 
rgapfrafo/y jywcy^a/ vin« and AArmg pnewmon&z 
ffioMOM A6fopMgwmov;n*$ and Tlwtey 
rAmofrocAgzfM v;rw 
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Table 2. Human RSV proteins, weight and putative Amotion (33,128, 162) 
RSV Molecular weight Putative functions) 
protein (kDa) 
NS1 14 Non structural protein; host interferon antagonist? 
NS2 15 Non structural protein; host interferon antagonist? 
N 43 Major nucleocapsid protein; binds viral RNA 
P 27 Nucleocapsid phosphoprotein; chaperone and polymerase cofactor 
M 28 Matrix protein; virion assembly 
SH 7 Small hydrophobic transmembrane protein; function undefined 
G 32 Transmembrane attachment glycoprotein; neutralization and protective 
antigen 
F 63 Transmembrane fusion glycoprotein; virus penetration and syncytia 
formation; neutralization and protective antigen 
M2-1 22 Transcription factor 
M2-2 10 Regulatory protein; down regulates transcription and up regulates 
RNA replication 
L 250 Polymerase 
Table 3. Human PIV3 proteins, weight and putative Amotion (68) 
PTV3 Molecular weight Putative function(s) 
protein (kDa) 
N 58 Major nucleocapsid protein; binds viral RNA 
P 60 Nucleocapsid phosphoprotein; chaperone and polymerase cofactor 
M 40 Matrix protein; virion assembly 
HN 69 Viral attachment and release; major protective antigen 
F 60 Transmembrane fusion glycoprotein; virus penetration and syncytia 
formation; neutralization and protective antigen 
L 250 Polymerase 
CHAPTER 2. REDUCED CLEARANCE OF RESPIRATORY SYNCYTIAL VIRUS 
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A paper submitted to Af/cmbes and /n/ecffon 
David K. Meyerholz, Branka Grubor, Sasha J. Fach, Randy E. Sacco, Howard D. 
Lehmkuhl, Jack M. Gallup, Mark R. Ackermann 
Abstract 
Respiratory syncytial virus (RSV) causes significant respiratory disease in 
children worldwide. For the study of severe RSV disease seen in preterm infants, a 
suitable animal model is lacking. The novel hypothesis of this study was that preterm 
lambs are susceptible to bovine RSV infection, an analogous pneumovirus with 
ruminant host-specificity, and that there would be age-dependent differences in 
select RSV disease parameters. During RSV infection, preterm lambs had elevated 
temperatures and respiration rates with mild anorexia and cough compared to 
controls. Gross lesions included multifocal consolidation and atelectasis with foci of 
hyperinflation. Microscopic lesions included multifocal alveolar septal thickening and 
bronchiolitis. Immunohistochemistry localized the RSV antigen to all layers of 
bronchiolar epithelium from a few basal cells to numerous sloughing epithelia. A few 
mononuclear cells were also immunoreactive. To assess for age-dependent 
differences in RSV infection, neonatal lambs were infected similarly to the preterm 
lambs or with a high-titer viral inoculum. Using morphometry at day 7 of infection, 
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preterm lambs had significantly more cellular immunoreactivity for RSV antigen 
(p<0.05) and syncytial cell formation (p<0.05) than either group of neonatal lambs. 
This work suggests perinatal RSV clearance is age-dependent, which may explain 
the severity of RSV infection in preterm infants. The preterm lamb model is useful for 
assessing age-dependent mechanisms of severe RSV infection. 
1. Introduction 
Respiratory syncytial virus (RSV) infection is a globally important respiratory 
disease of infants and children. In the United States alone RSV infection is the most 
common cause of respiratory disease leading to hospitalization in children costing 
an estimated $300 to $400 million annually [1, 2]. RSV is the major cause of 
bronchiolitis in children and the incidence of bronchiolitis hospitalization in children 
under 1 year of age increased 2.4 fold from 1980 to 1996 [3, 4]. Infection is 
ubiquitous and most children have been infected by 2 years of age [5], Currently, 
there is no efficacious treatment for severe RSV infection and supportive treatment 
during hospitalization includes: bronchodilators, fluid therapy, and oxygen 
management with more severe cases receiving corticosteroids or antiviral agents 
(e.g. ribavirin) [6]. Vaccine development has been slow and cautious following a 
1960's vaccine trial in which some vaccinates developed severe disease following 
natural RSV exposure [7]. Recent developments include a humanized monoclonal 
antibody (Palivizumab) against the fusion (F) protein which can prevent severe 
manifestations of RSV disease that require hospitalization, but it does not prevent 
infection. Because of the high costs of individual treatment the use of Palivizumab is 
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often restricted to high risk patients. Patients with increased risk for hospitalization 
and mortality due to severe RSV disease include preterm and young neonatal 
infants [3, 7, 8]. 
Currently, there is no well-recognized model for the study of the severe RSV 
disease associated with preterm and young neonatal infants. Research of severe 
RSV infection in infants is limited by technical difficulty, practical and ethical 
concerns [9]. Study of RSV infection in animal models requires comparable clinical 
disease, lesion development, immunity, or other features that relate to the specific 
aims of the experiment [10]. Animal models for study of human RSV (hRSV) 
pathogenesis and immune response include rats [11], mice [12], ferrets [13], guinea 
pigs [14], hamsters [15], lambs [16] and nonhuman primates [17]. Infection in the 
chimpanzee is viewed by some to be the most analogous to human disease, 
however, animal availability is limited, few are naive and they require specialized 
facilities and management making this model impractical [18]. Mice are often used in 
models for human disease (including RSV) because of the ease of handling and 
availability of strains with specific knockout genes [12]. However, hRSV infection in 
rodents produces only mild bronchitis without overt respiratory disease making 
distinctions about severe infection difficult. 
Late term fetal and preterm lambs have proven valuable as pulmonary 
models for the study of surfactant expression and regulation [19], ventilation-induced 
injury [20], congenital diaphragmatic hernia [21], chorioamnionitis [22], sleep apnea 
[16] and persistent pulmonary hypertension of the newborn [23]. A preterm lamb 
model of hRSV was previously evaluated for RSV-induced sleep apnea and infection 
60 
yielded only mild clinical disease [16]. An analogous virus model is bovine RSV 
(bRSV), a pneumovirus that is genomically, antigenically and functionally related to 
hRSV and is host-adapted for ruminant infection causing significant pulmonary 
lesions and clinical disease [18, 24, 25]. The preterm lamb model of bRSV infection 
has not been assessed for use as a model of RSV disease and lesions. Previous 
work in the sheep suggested bRSV infection may cause more severe lesions in 
neonatal versus 6-month old lambs [25, 26]. Furthermore, study of hRSV infection in 
senile cotton rats suggested age-dependent mechanisms for RSV clearance [11]. 
Since developmental age is a determinant in severity of RSV disease and lesions, 
bRSV infection in the preterm lambs could be a novel model for studying the severity 
of RSV disease in preterm infants. The hypothesis of this study was that preterm 
lambs are susceptible to bRSV infection and that bRSV activity would be age 
dependent in the perinatal lamb. 
2. Materials and methods 
2.1. Animals 
Healthy, date-mated commercial ewes were acquired from Iowa State 
University's Laboratory Animal Services. A gestational age of 138 days (term -147 
days) was chosen to provide a preterm lamb which would not require mechanical 
ventilation, a known instigator of pulmonary injury [20]. Following removal via 
surgical uterotomy, lambs were given tactile stimulation with manual chest 
compressions (if necessary) until respiration was self-regulated, then dried and 
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placed in a thermo-regulated pen. Within the first hour, fresh colostrum (-200 ml) 
was given via a stomach tube and ceftiofur (2.2 mg/kg/day, intramuscular) was given 
to prevent potential bacterial complications [27]. Lambs were hand-fed commercial 
milk replacer four times daily and milk consumption recorded. In addition, body 
temperatures and respiration rates were recorded at the same time each day 
following the morning feeding. Lambs were inoculated at one day of age as follows: 
the cervical midline was sanitized with 70% ethanol and the trachea isolated for 
intratracheal injection (20 cc's) of viral inoculum (n=6) or sterile media (n=6). 
In addition, eleven neonatal lambs (2-4 days of age) were acquired from Iowa 
State University's Laboratory Animal Resources and inoculated with bRSV similarly 
to the preterm lambs one day following arrival. Five of the lambs were inoculated 
with the same virus inoculum as preterm lambs, three lambs received high-titered 
viral inoculum and the remaining three received sterile media as a control. 
2.2. Virus 
Bovine RSV (bRSV) strain-375 was grown in flasks containing adherent 
bovine turbinate cells (5 % COz and 37 ° C). When 90% of virus-induced cytopathic 
effect was visible (usually within 7 days), the flasks were frozen (-80 ° C) and then 
thawed the next day. All flask media was pooled, thoroughly mixed, sterile filtered 
and aliquoted. The aliquots were stored at -80 ° C. One aliquot was used to 
determine the tissue culture infective dose (TCIDso/ml) by standard plaque assay 
and the virus titer ranged from lO^TCIDso/ml. For the second group of neonatal 
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lambs, further passages were made to produce a high-dose inoculum with a titer 1 (f 
TCIDso/ml. 
2.3. Tissue 
On day 7 of infection, lambs (preterm and neonatal) were euthanized with an 
intravenous injection of sodium pentobarbital. From our preliminary work with bRSV 
in neonatal lambs, day 7 was chosen because this is approximately when the most 
severe lesions are seen and when clearance of RSV antigen is underway [28]. The 
thorax was opened and the lungs examined for gross lesions. The lungs were then 
removed from the thorax for subsequent tissue collection. The lung was consistently 
sampled from the left and right: cranial, middle and caudal lobes. Tissues were 
placed in 10 % buffered formalin and processed routinely for hematoxylin and eosin 
staining or immunohistochemistry. 
2.4. Immunohistochemistry 
Sections of lung on silanated glass slides were stained with antibody to RSV 
antigen using a streptavidin-biotin-peroxidase method developed in our laboratory. 
Briefly, slides of lung tissue were heated to 58 ° C for 20 minutes and deparaffinized 
through a series of ethanol and xylene baths. Antigen retrieval was performed by 
applying "Pronase E" (0.1 g Protease XIV [Sigma, St. Louis, Mo ] and 0.1 g CaCb 
per 100 mL TBS pH 7.6) on heated slides for 10 minutes followed by TRIS [pH 7.6] 
(5x's) and PBS (Biogenex, San Ramon, OA) washes (2x's). Normal swine serum (20 
% for twenty minutes) was applied as a non specific blocker followed by primary 
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antibody (mouse monoclonal anti-BRSV-4 [courtesy of Dr. Ken Piatt, Iowa State 
University], 1:100, with normal swine serum [5%] and normal goat serum [5 %]) for 
72 hours at 4° C. Slides were warmed to room temperature followed by multiple PBS 
washes. Endogenous peroxidases were blocked by a forty minute application of 
hydrogen peroxide (3 %) in PBS and then repeated PBS washes. Secondary 
antibody (1:300 biotinylated goat anti-mouse [Kirkegaard & Perry Laboratories, 
Gaithersburg, MD] with normal swine serum [15 %]) was applied for 45 minutes 
followed by multiple PBS washings. Next the slides were treated with streptavidin-
conjugated horseradish peroxidase (Biogenex, San Ramon, CA, 45 minutes), 
multiple PBS washes, and the chromogen Nova Red (Vector, Burlingame, CA, 5 
minutes). The slides were washed in PBS, counterstained with Harris' hematoxylin, 
dehydrated through a series of ethanol and xylene baths and cover slipped. 
2.5. Morphometry 
The purpose of the morphometry was to quantify the number of cells staining 
for bRSV antigen in lesions. Sections of lung from the right and left cranial lobes 
were used for the study. Since bRSV lesions and immunoreactivity were principally 
in and around small bronchioles, a pathologist (blinded from the study) randomly 
selected from low power bronchioles within lesions. At higher magnification, a grid 
[29] was centered over the bronchiole and adjacent tissue with the total number of 
positive cells and morphological cell-type being recorded (area = 440 x 440 pm [10^ 
pnf ]) At this same time counts for syncytial cells and mitosis were performed. A 
64 
total of ten bronchiolar lesions were counted from the left and right sides and 
averaged. 
2.6. Statistics 
For clinical data the group means on each day were analyzed for significance 
using pair-wise t-tests. In the morphometry experiments, the resulting data was 
analyzed using the Wilcoxon-Mann-Whitney test. For all data, significance was 
placed at p < 0.05. 
3. Results 
Clinical scores for the lambs included body temperature, respiration rate and 
milk consumption (Table 1). The infected preterm lambs had slightly higher 
temperatures than control lambs throughout the infection with significantly higher 
temperatures on days two and three of infection (p<0.05). In the infected group, 
temperatures peaked on day two to three of infection with a decrease until day five 
with another slight increase starting on days six to seven of infection. From day three 
through the course of the infection, respiratory rates for the infected group were 
slightly higher than controls with significant elevation on days five and six of infection 
(p<0.05). Milk consumption was slightly reduced in the bRSV group through the 
course of the infection. Infected lambs had a mild cough most noticeable upon 
exertion. 
In regards to preterm lambs and susceptibility to bRSV, all of the infected 
lambs developed lung lesions while the control lungs were normal. Grossly, the 
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lungs had multiple plum-red foci (2-10 mm) of consolidation that was slightly 
depressed from the adjacent pleural surface. On cut-surface, the lesions were 
slightly firm with well-defined borders. The lesions were most evident on the ventral 
half of the lungs with accentuation in the cranial and hilar regions. Adjacent to the 
consolidated lesions were pale-pink hyperinflated areas of lung. 
Microscopically, there were multifocal areas in which alveolar septa were 
thickened by macrophages, lymphocytes, plasma cells with small numbers of 
neutrophils and moderate vascular congestion (Fig. 1-3). Intralesional bronchioles 
had luminal neutrophils, sloughed epithelial cells and lesser amounts of 
macrophages with eosinophilic cellular and karyorrhectic debris (Fig. 4). Bronchiolar 
epithelium was often thickened by hyperplasia of epithelial cells, many of which had 
mitotic figures. There were also multiple moderate infiltrates of neutrophils and areas 
of necrosis. In addition, bronchioles had a small number of individual apoptotic cells 
usually within cytoplasmic vacuoles of adjacent epithelia or mononuclear cells. A 
small number of the epithelial cells were multinucleated (as syncytial cells) and/or 
contained small (3-5 p,m) intracytoplasmic eosinophilic structures consistent with 
viral inclusion bodies. 
Immunohistochemistry was used to confirm the presence of bRSV antigen 
and localize the sites of cellular replication. Sections of control lung were 
consistently negative. In infected lung, all levels of bronchiolar epithelium were 
immunoreactive for bRSV antigen including a few basal cells to several sloughing 
epithelial cells (Fig. 5). Within lesions, a few mononuclear cells were immunoreactive 
and most had a vacuolated to foamy cytoplasms that were morphologically 
consistent with macrophages. The granular cytoplasmic staining of immunoreactive 
epithelial and mononuclear cells was characterized by small globular structures 
(-0.5 to 8 pm) within the cytoplasm and was consistent with viral inclusions. A 
smaller number of neutrophils contained antigen. These were often degenerate, 
found only in the lumen of connecting airways and lack distinct globular structures 
(inclusions) seen in other infected cells. 
Cellular immunoreactivity, syncytial cell formation and mitotic index were used 
to assess RSV activity and host repair in the preterm versus neonatal lamb. The 
preterm lambs had more cellular reactivity for bRSV antigen than did neonatal lambs 
with similar inocula (p<0.05) or high-titer inocula (p<0.05) (Fig. 6, A). Two out of the 
five lambs in neonatal group 1 (similar virus titer) and one out of three lambs in 
neonatal group 2 (high virus titer) lacked evidence of immunoreactivity while all of 
the preterm infected lambs had ample bRSV antigen. The syncytial cell formation, 
indicative of RSV activity, was significantly higher in the preterm group compared to 
either of the neonatal bRSV groups (p<0.05) (Fig. 6, B). The mitotic rate, an indicator 
of reparative hyperplasia, was similar between the different groups (Fig. 6, C). 
4. Discussion 
The hypothesis of this study was that preterm lambs would develop bRSV 
disease and that bRSV antigen distribution at the time of clearance would be more 
widespread in preterm versus full term neonatal lambs. The RSV infected preterm 
lambs showed clinical evidence of infection including elevated temperature and 
increased respiration rate with mild loss of appetite (milk consumption) and cough. 
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The pyrexia and tachypnea are consistent with previous work in older neonatal 
lambs with hRSV or bRSV infection [16, 25]. Infants with severe hRSV infection 
typically exhibit a low-grade to moderate fever, croup-like cough and tachypnea with 
anorexia, lethargy or irritability [3]. The clinical signs in the preterm lambs paralleled 
many features of severe hRSV infection in infants but notably lacked the severe 
croup-like cough. This lack of severe cough is similar to previous work in lambs with 
bRSV [30], but may also be, in part, a consequence of the mid-tracheal inoculation 
which would have minimized exposure of the upper tracheal and laryngeal 
epithelium to bRSV for development of laryngotracheitis. 
All infected lambs had gross lesions while the controls lacked lesions. The 
cranioventral to hilar distribution of the lesions was likely a partial result of the 
aspiration-like allocation of viral media following inoculation and is similar to other 
work [28]. Gross lung lesions were composed of multifocal atelectasis and 
consolidation with hyperinflation. Infants with severe hRSV infection can have 
radiographic evidence of interstitial lung patterns with foci of atelectasis, 
peribronchiolar thickening and hyperinflation which corresponds to lesions in this 
study [31]. 
Histologically, a bronchointerstitial pattern was seen in multiple foci with 
primarily a mononuclear (macrophages and lymphocytes) infiltrate and congestion in 
alveolar septa. Severe RSV infection in infants is associated with elevated 
chemokine levels including RANTES (CC chemokine ligand 5 [CCL5]) and 
macrophage inflammatory protein-1a (CCL3) which are chemotactic for monocytes 
and other leukocytes [31-33]. RSV-induced chemokine expression likely provided 
the means for the mononuclear leukocyte infiltrate. 
The intralesional bronchioles were characterized by epithelial sloughing, 
necrosis, and hyperplasia with infiltrates of neutrophils. Leukocyte populations of the 
connecting airway in severe RSV infection are typically composed of neutrophils and 
they participate in the viral immunopathology [34]. Epithelial sloughing and necrosis 
is, in part, a direct result of neutrophil adhesion and exocytosis [35]. RSV infection of 
epithelial cells and monocytes leads to a synergistic up-regulation in expression of 
interleukin-8 (IL-8), a CXC chemokine that enhances neutrophilic chemotaxis, and 
enhanced IL-8 expression is correlated with severe RSV infection [36, 37]. An 
additional source for epithelial cellular debris is apoptosis, a common mechanism for 
clearance of RSV infected epithelia [27]. 
Adjacent bronchiolar epithelium was hyperplastic which is indicative of 
epithelial repair [38]. The mitotic rate, an indicator of the degree of hyperplasia, was 
similar between the preterm and neonatal lambs. This present study suggests 
reduced repair capacity is not likely a factor in severe RSV disease. 
Staining for bRSV antigen was present only in infected lambs and was 
localized to the bronchiolar epithelium with some mononuclear cells. Recently, 
putative receptor(s) for RSV were described to have L-selectin-like properties [39]. 
L-selectin is a member of the adhesion-molecule selectin family and is important in 
leukocyte tethering for endothelial transmigration during normal trafficking or at sites 
of inflammation [40]. One of the proposed RSV receptors was further characterized 
as annexin II [39]. Annexin II belongs to the annexin family of calcium- and 
phospholipid-binding proteins. In the lung, annexin II is selectively expressed in 
basal cells, but not columnar cells of the respiratory epithelium [41]. Infection of 
basal cells would be advantageous for RSV biologically in allowing adequate time 
during normal cell turnover for viral replication. While a few basal cells contained 
antigen, most staining was in the sloughing epithelial cells which may correspond to 
the chronological turnover of previously infected basal cells at inoculation. 
The immunoreactivity in mononuclear cells and neutrophils could be due to 
direct virus infection or phagocytosis of infected cellular debris. Direct infection is 
possible via putative receptors such as L-selectin-like moieties found on most 
leukocytes or annexin II which has been localized to monocytes [40, 42]. 
Ultrastructurally, macrophages of calves infected with bRSV show viral inclusions in 
the cytoplasm consistent with infection [43]. Most of the mononuclear cell staining in 
this current study was morphologically consistent with macrophages, and given the 
intracytoplasmic viral inclusions, direct RSV infection of macrophages was most 
likely. Other mononuclear cells such as dendritic cells and lymphocytes cannot be 
excluded as in vitro studies have shown capacity for RSV uptake [44,45]. As for 
neutrophil antigen accumulation, phagocytosis of sloughed infected cellular debris in 
airways probably allowed for much of the neutrophil staining since there was a lack 
of distinct cytoplasmic inclusions and the quick demise of the degenerate neutrophil 
following exocytosis into the airway lumen would prevent opportunity for adequate 
viral replication. 
Preterm lambs had significantly more immunoreactive cells and syncytial cell 
formation than did neonatal lambs with similar (lO^TCIDso/ml) or even higher (10^ 
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TCIDso/ml) virus inoculum. The timing of RSV clearance as assessed by virus 
isolation, closely parallels staining for bRSV antigen by immunohistochemistry [28]. 
Syncytial cell formation is, in part, a by-product of the RSV fusion (F) protein and an 
indicator of RSV activity [46]. The increased bRSV immunoreactivity and syncytial 
cell formation in the preterm lambs are indicative of a reduced capacity to clear the 
virus compared to the neonatal lambs. Similar age-dependent differences in viral 
clearance were seen while studying severe hRSV disease as senile versus young 
adult cotton rats were less efficient at viral clearance [11]. Reduced RSV clearance 
in the preterm infant would prolong and perhaps exacerbate inflammation leading to 
severe clinical disease. 
Viral clearance in bRSV infected calves is primarily mediated through 
apoptosis of infected cells with phagocytic removal of the apoptotic bodies by 
adjacent epithelial cells or monocytic cells [27]. In cultured respiratory epithelia, RSV 
infection directly results in expression of many pro- and anti-apoptotic factors. The 
intracellular balance of these factors may be pushed towards apoptosis through 
external mononuclear-induced cytotoxicity by binding of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) to death receptor-4/-5 (DR4/5) [47]. TRAIL 
is quickly expressed on monocytes following interferon-a or activation (common 
with RSV infection) and subsequent binding of DR4/5 expressing cells causes 
induction of apoptosis [48]. Interestingly, lamb monocytes infected with bovine RSV 
have decreased phagocytosis and antigen presentation ability [49]. In addition, 
preterm lamb monocytes have delayed hydrogen peroxide production and reduced 
phagocytosis of apoptotic cells compared to monocytes from neonatal lambs [50]. 
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Decreased monocytic function in the RSV infected preterm infant may contribute to 
lack of RSV clearance and thus allow for severe RSV disease. 
In this study, we highlight the novel use of bRSV infection in the preterm 
lamb, which exhibits clinical signs and comparable lesions to severe hRSV disease 
in the preterm infant. Furthermore, preterm lambs have reduced capacity for RSV 
antigen clearance compared to neonatal lambs. The preterm lamb model is useful to 
study age-dependent differences seen in severe RSV infection of preterm infants. 
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Table 
Table 1. Average body temperature, respiration rate and daily milk consumption by control 
and RSV infected preterm lambs. 
Day of Group Temperatures Respiratory rate Daily milk consumptic 
infection (° C +/- sem) (respirations/minute +/- sem) (milliliters +/- sem) 
Day 1 Control 39.44+/-0.17 61 +/- 6.3 . . .  
RSV 39.69+/-0.11 57+/-1.3 . . .  
Day 2 Control 39.74 +/- 0.06 64 +/- 3.3 563.3 +/-102.0 
RSV 39.98 +/- 0.05* 60 +/- 2.2 498.3 +/- 47.8 
Day 3 Control 39.57+/-0.13 60+/-3.8 607.5 +/- 84.6 
RSV 39.95 +/- 0.05* 65 +/- 2.9 583.5 +/- 78.3 
Day 4 Control 39.69+/-0.06 59+/-1.8 815.8+/-107.7 
RSV 39.78 +/- 0.07 64 +/- 4.8 657.5 +/- 80.5 
Day 5 Control 39.59+/-0.11 50 +/- 3.0 841.7 +/-100.3 
RSV 39.63 +/- 0.16 68 +/- 5.0' 676.7+/-63.3 
Day 6 Control 39.7+/-0.1 52+/-4.0 892.5+/-91.1 
RSV 39.78 +/- 0.05 64 +/- 3.3' 764.2+/-69.7 
Day 7 Control 39.69 +/- 0.04 49+/-1.8 903.3 +/-106.2 
RSV 39.87+/-0.15 55 +/-1.8 785.8 +/-103.6 
* RSV group compared to control group (p < 0.05) 
Figures 
Fig. 1: Control lungs from lambs given sterile media lacked lesions, bar = 500 pm. 
Fig. 2: bRSV-infected lungs had multiple foci of bronchointerstitial consolidation, bar 
= 500 fim. 
Fig. 3: Within lesions, the alveolar septa were thickened by predominantly 
mononuclear infiltrates, bar =100 pm. 
Fig. 4: Infected bronchiolar epithelium was thickened by hyperplasia with multiple 
mitotic figures (arrows) and neutrophilic necrotic cellular debris in the lumen. Note 
the syncytial cell formation (arrowhead), bar = 25 pm. 
84 
Fig. 5: Staining for bRSV antigen was primarily within bronchiolar epithelium and a 
few mononuclear cells (arrow), bar = 25 pm. 
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Fig. 6: Morphometry of cellular staining for bRSV antigen, syncytial cell formation 
and mitotic rate in bRSV inoculated preterm (20ml x lO^TCIDso/ml) and neonatal 
(20ml x lO^TCIDso/ml or lO^TCIDa/ml) lambs. A: The cellular staining for bRSV 
antigen was greater in the preterm versus either neonate group (p<0.05). All preterm 
lambs had strong staining while the neonate group had reduced individual staining 
including two of five lambs in neonate-IO^TCIDso/ml and one of three lambs in 
neonate-IO^TCIDso/ml which were negative for staining. B: Syncytial cell formation, 
indicative of bRSV activity, was greater in the preterm lambs compared to either of 
the neonate groups (p<0.05). G: The mitotic rate, a marker for the degree of 
reparative hyperplasia, was similar between the preterm and neonatal groups. 
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CHAPTER 3. DEVELOPMENTAL EXPRESSION AND DISTRIBUTION OF SHEEP 
BETA-DEFENSIN-2 
A paper published in 
Deye/opmenfa/and CompamGye /mmuno/ogy 2004, 28:171-178. 
David K. Meyerholz, Jack M. Gallup, Branka M. Grubor, Richard B. Evans, Brian F. 
Tack, Paul B. McCray Jr., Mark R. Ackermann. 
Abstract 
The aim of this study was to define the ontogeny of sheep beta-defensin-2 
(SBD-2) mRNA and peptide in selected tissues of fetal, neonatal and adult sheep by 
real-time PGR and immunohistochemistry, respectively. Fetal and neonatal lambs 
had a significantly greater SBD-2 tissue distribution than adult sheep. For all ages, 
the intestines had consistent SBD-2 mRNA expression while extra intestinal 
expression was sporadic and weak. In adult sheep, SBD-2 mRNA levels decreased 
from the jejunum caudally to the rectum and a pooled sample from all age groups 
showed a similar tendency. SBD-2 immunoreactive cells were predominantly in the 
crypts and base of villi in the small intestine and in a modest number of glands in the 
large intestine. Interestingly, ileal follicle-associated epithelium lacked detectable 
SBD-2 immunoreactivity. SBD-2 mRNA and peptide expression are greatest in the 
intestinal tract and tissue distribution progressively decreases with maturity. 
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1. Introduction 
Antimicrobial peptides are widespread in nature including plant and animal 
kingdoms and provide innate microcidal protection for the host [1]. Defensins are a 
subclass of antimicrobial peptides defined by a cationic charge, antimicrobial activity 
and six to eight highly conserved cysteine residues that form intramolecular disulfide 
bonds. There are three families of defensins including alpha-, beta- and theta-
defensins each characterized by the type of intramolecular disulfide bonds [2]. 
Beta-defensins have a conserved structure with six-cysteine residues and in 
humans there are five defined beta-defensin genes. However, a recent 
computational search has identified an additional 28 putative beta-defensin genes 
[3]. Beta-defensins have demonstrated antimicrobial activity against several 
bacteria, fungi and enveloped viruses [1,4,5]. Alterations of the cationic charge or 
specific amino acid substitutions between defensins correlate with the spectrum of 
antimicrobial activity. The distribution of beta-defensins at mucosal surfaces 
(respiratory, gastrointestinal, urogenital, etc) and glands make them an important 
first line of defense against pathogens [6]. 
Recently, two sheep beta-defensins (sheep beta-defensin-1 [SBD-1] and 
sheep beta-defensin-2 [SBD-2]) genes were identified and mapped to sheep 
chromosome 26 [7]. An additional study of SBD-2 mRNA expression in the 
gastrointestinal tract of various aged sheep suggested developmental regulation of 
SBD-2 before and after birth [8]. SBD-2 mRNA tissue distribution, 
immunohistochemical localization and developmental expression has not been fully 
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determined. The purpose of this study was to define SBD-2 expression and 
distribution in select ovine tissues during ontogeny. 
2. Materials and Methods 
2.1 Animals 
Three fetuses (120-140 days gestation [145 days term]), three neonates (3-5 
days of age) and three adult sheep with no clinical disease were used for this study. 
Individual animals were euthanized by intravenous sodium pentobarbital as 
approved by the animal care and use committee. Tissues collected included nasal 
turbinate, trachea, lung, rumen, abomasum, jejunum, ileum, spiral colon, rectum, 
liver, gall bladder, urinary bladder, kidney, uterus (adult) and placenta (fetus). 
Tissues were both placed in 10% buffered formalin for immunohistochemistry, and 
snap-frozen in liquid nitrogen for Reverse Transcriptase synthesized cDNA-
catalyzed fluorogenic TaqMan real-time PGR (hereafter - real-time PGR). 
2.2 Ribonucleic acid isolation 
RNA was isolated from each tissue using Trizol reagent [9] by a procedure 
that was a slight modification of the protocol suggested by the manufacturer's 
instructions (Invitrogen). Briefly, 0.3 g of tissue and 3 ml of Trizol reagent were 
homogenized for 30 seconds and the homogenate was allowed to sit for 5 minutes 
at room temperature. Chloroform (0.6 ml) was added and the mixture was shaken 
vigorously for 15 seconds then allowed to sit for 3 minutes at room temperature. This 
mixture was microfuged for 10 minutes at 4°C, and the resulting top aqueous layer 
was retrieved and mixed with isopropanol (1.5 ml) and allowed to sit for 10 minutes 
at room temperature. The solution was again microfuged for 10 minutes at 4° C, the 
aqueous/isopropanol layer removed and the visible pellet resolubilized in nuclease-
free HPLC-grade water containing 0.1 mM EDTA. Spectrophotometer 
measurements were then taken of each RNA isolate (detection at 260nm and 
280nm absorbances of 1:40 sample dilutions) to assess the isolates for purity and 
quantity. 
2.3 Complementary deoxyribonucleic acid production 
Deoxyribonuclease (DNase) treatment of RNA samples was performed to 
remove potential genomic deoxyribonucleic acid (DNA) contamination with a 
commercially available DNase (RQ1 RNase-Free DNase, Promega) following 
manufacturer's directions and using the following thermocycler (GeneAmp PGR 
System 2400, Perkin Elmer) conditions: 30 minutes at 37° C (to degrade any 
contaminating genomic DNA), program was then halted while RQ1 DNAse Stop 
solution (Promega) was added to each tube, tubes were vortexed and returned to 
the thermocycler to resume with a ten minute incubation at 65° C, and a final safety 
hold at 4° C. Immediately after this, reverse transcription was performed with a 
commercially available kit (TaqMan Reverse Transcriptase Reagents, PE 
Biosystems) following manufacturer's directions. Briefly, 2 pg of DNase-treated RNA 
from each sample and control were added to a reaction mixture which contained 
final concentrations of 1X TaqMan RT buffer, 5.5 mM MgCb, 2 mM 
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deoxyribonucleoside triphosphate (dNTP) mixture (500 pM each dNTP), 2.5 pM 
random hexamers, 1.25 U/pl murine leukemia virus (MuLV) RT, 0.4-0.8 U/pl 
ribonuclease (RNase) inhibitor and HPLC-grade water. The following thermocycler 
conditions were then used: 10 minutes @ 25° C, 30 minutes @ 48° C and 5 minutes 
@ 95° C. Resulting cDNA was stored in nuclease-free microcentrifuge tubes at -20° 
C. 
2.4 Primer and Probe Design 
Sequence-specific oligonucleotide primers and a fluorescent probe for 
detection and relative quantification of cDNA corresponding to the target gene (SBD-
2) were designed with software (ABI Prism Primer Express, Version 1.5, PE Applied 
Biosystems) according to the software manufacturer's suggestions, and were 
engineered to be within the coding sequence of the mRNA. Resultant potential 
primer and probe sequences were compared to all available DNA sequence 
databases via the search tool BLAST (Basic Local Alignment Search Tool, Version 
1.4, National Center for Biotechnology Information) for similarity, and only unique 
sequences were used for primer and probe design. SBD-2 nucleic acid sequences 
included the following: 
forward primer - 5AAGCTGCCGTTGGAAGAAAG3'; 
reverse primer - 5CCCGAAACAGGTGCCAATC3'; 
and probe: 5'6FAM-TGTGTGCTGACCAAGTGCCCTGGAACCATGAG-TAMRA3' 
(6FAM = Fluorescent reporter dye, TANIRA = Fluorescent quencher dye). 
91 
Sequence-specific oligonucleotide primers and a fluorescent probe for detection of 
cDNA corresponding to the endogenous reference gene, 18S Ribosomal RNA, to 
which SBD-2 cDNA levels would be normalized, were purchased commercially 
(TaqMan Ribosomal RNA Control Reagents, PE Biosystems). 
2.5 Polymerase Chain Reaction 
Five separate 96-microwell plates (PE Biosystems) were designed to enable 
PGR using cDNA from all sheep, with three replicates run for each sheep, as well as 
three replicates run of a negative control (DEPC-treated water), on each plate. In 
addition, on each plate were three replicates each of five progressive 1:5 dilutions of 
cDNA from a control sheep (Sheep #265) that served in the generation of a standard 
curve, as well as three replicates containing cDNA from a sheep (Fetus #5, ileum) 
that served as a calibrator to which all other cDNA values would later be compared 
during analysis. On each plate, target and endogenous reference PGR wells were 
run simultaneously for the sheep represented on that plate. The assay composition 
was as follows: the 50 pi PGR mixtures contained 25 pi of the commercially 
available master mix (Taqman Universal PGR Master Mix - 2X Concentration, PE 
Biosystems); 5 pi of a 1:5 dilution of cDNA (or DEPC-treated water for the negative 
control); SBD-2 forward primer, reverse primer and probe concentrations of 300 nM, 
900 nM and 150 nM, respectively, or 50 nM, 50 nM and 200 nM, respectively, for the 
endogenous control of 18S rRNA (PE Biosystems); and DEPC-treated water. This 
plate was run in the sequence detection system (GeneAmp 5700 Sequence 
Detection System, Version 1.3, Applied Biosystems) with conditions identical to 
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those used in the optimization and validation tests. Resultant data gathered by the 
detection system was exported from the machine to floppy disk, and all final data 
processing was performed using a departmentally-designed EXCEL file to compare 
target to reference cDNA signals in order to create relative mRNA expression 
graphs. 
2.6 Immunohistochemistry 
The SBD-2 primary antibody was generated in rabbits inoculated with a 
synthesized SBD-2 peptide. This peptide was purified by high performance liquid 
chromatography, assessed by matrix-assisted laser desorption/ionization-mass 
spectrophotometry for molecular weight, and in western blots the antibody bound the 
synthesized 42 amino acid SBD-2 peptide as well as a band from ileum 
homogenates at the appropriate molecular weight of 4.6 kDa. Paraffin-embedded 
tissues were cut (6-microns) and placed on glass slides. These were deparaffinized 
in xylene followed by a series of ethanol baths and washed (PBS/0.1% Tween 20). 
Normal swine serum (30%) was applied for 30 minutes for nonspecific protein block. 
Next the primary antibody (polyclonal rabbit anti-SBD-2 [1:5000 in BioGenex Diluent] 
with 5% normal goat serum and 5% normal swine serum) was applied to the tissue 
in 5-slide plastic mailers for 72 hours at 4° C. Slides were allowed to warm to room 
temperature, washed, then a secondary antibody (biotinylated Goat anti-Rabbit 
[Kirkegaard & Perry Labs], 1:400 in BioGenex Diluent with 25% normal swine 
serum) was applied for 45 minutes followed by multiple washing baths. The 
chromogen (Vector Nova Red) was applied for five minutes followed by multiple 
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water washes. The tissues were counterstained with hematoxylin, dehydrated 
through a series of ethanol and xylene baths and cover slipped with Permount. 
2.7 Statistical analysis 
Pair wise t-tests were used to assess differences in age/tissue group means. 
In order to assess the intestinal SBD-2 expression trend, linear regression was used 
to calculate the sign (+/-) of the slope coefficient. The statistical analysis for SBD-2 
mRNA tissue distribution was done with the nonparametric Wilcoxon test. 
3. Results 
The aim of this study was to define the expression and cellular distribution of 
SBD-2 in select tissues during ontogeny. We utilized real-time PGR for SBD-2 
mRNA tissue expression and immunohistochemistry for SBD-2 cellular distribution. 
3.1 Real-time PGR 
SBD-2 mRNA levels were highly variable between individual animals even of 
the same age group. This contributed to the lack of statistical significance in SBD-2 
expression among age or tissue group means. The jejunum had the highest SBD-2 
mRNA expression for all individuals. In addition all individuals had SBD-2 mRNA 
consistently expressed in the jejunum, ileum, spiral colon and rectum. In the adult 
sheep, relative SBD-2 mRNA expression progressively decreased from the jejunum 
to the rectum (Fig. 1 A, p = 0.008). The neonatal lambs had similar progressively 
decreasing expression in the intestinal tract, however the decrease was not 
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statistically significant due to the extensive individual variability (Fig. 1B). The fetal 
group had slightly lower relative expression values than the neonate and adult, but 
still had marked individual variability (Fig. 1C). When the tissues mRNA levels from 
all age groups were pooled, a general trend of decreased SBD-2 mRNA expression 
from jejunum to rectum (p = 0.052) was detected. 
While the intestinal SBD-2 mRNA was present in all individuals, other tissues 
had sporadic SBD-2 mRNA expression (Table 1). Extra-intestinal expression was 
present in the respiratory tract (turbinate, trachea, lung), urinary tract (kidney, urinary 
bladder), liver and uterus. The SBD-2 mRNA expression in these tissues was often a 
small fraction of the calibrator and the tissue distribution was variable among 
individuals. The fetal and neonatal lambs had wider tissue distribution of SBD-2 
mRNA than did adult sheep (p = 0.042, fetus/neonate lambs vs. adults). No SBD-2 
expression was evident by any age group in the rumen, abomasum, gall bladder or 
fetal placenta. 
3.2 Immunohistochemical detection of SBD-2 
Tissues with SBD-2 mRNA expression were examined for cellular distribution 
of SBD-2 peptide immunoreactivity. In jejunum, SBD-2 immunoreactivity was 
present within the epithelial cells of villus crypts (Fig. 2). Approximately 50% of the 
crypt cells were immunoreactive and staining was present throughout the cytoplasm 
in jejunum and other tissues; nuclei lacked immunoreactivity in all cells in all tissues. 
The number of epithelial cells in jejunum with immunoreactivity progressively 
decreased from the crypts to the lower base of villi. Enterocytes lining the luminal 
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two-thirds of the villus epithelium generally lacked immunoreactivity; only an 
occasional cell had immunoreactivity. Goblet cells located at the base of villi had 
mild/moderate immunoreactivity while those on the upper villus lacked staining. Ileal 
immunoreactivity was similar to that of the jejunum except that there were fewer 
cells with immunoreactivity in the crypts and villus epithelium. In the ileal Foyer's 
patches, the follicle-associated epithelium (FAE) lacked immunoreactivity (Fig. 3). 
The spiral colon and rectum both had a few to roughly 30% of glands with 
immunoreactivity of individual cells. Immunoreactive cells were rarely present in the 
luminal half of the gland. For all tissues, staining intensity and distribution was 
highest for the jejunum and progressively decreased to the rectum. This was true for 
all age groups. Immunoreactivity to SBD-2 peptide was not detected in extra­
intestinal tissues with low mRNA expression (data not shown). 
4. Discussion 
In this study we defined SBD-2 mRNA and peptide expression and 
distribution in the sheep fetus, neonate and adult. The amount of SBD-2 mRNA 
expression was highly variable between individuals, even in tissues with consistent 
expression, such as the intestinal tract. The individual variability of SBD-2 
expression was partially characterized in a previous SBD-2 study [8] and the 
variability of SBD-2 expression is similar to expression of alpha- and beta-defensins 
in human intestine [10]. Inflammatory cytokines, interactions with microbial 
pathogens, and cellular proliferation/differentiation are a few of the factors that can 
regulate beta-defensin expression [1,11,12]. The individual variability of SBD-2 and 
other intestinal defensins may reflect a dynamic multifactorial influence by the local 
environment in defensin regulation and expression. 
All individuals had SBD-2 mRNA expression consistently in the intestines and 
individual expression was highest in jejunum. The immunoreactivity of SBD-2 
peptide was highest in the jejunum and corresponded to the jejunal mRNA 
expression of SBD-2. The relative expression of SBD-2 mRNA in the small and large 
intestine is similar to that of human alpha-defensins (HD5 and HD6), which are a 
component of Paneth cell secretory granules [10]. Paneth cells are specialized cells 
in the crypts of Lieberkuhn that can influence the local microbial environment and 
contribute to the mucosal barrier by their secretions including antimicrobial peptides 
[13]. In our study, SBD-2 immunoreactivity was principally present in crypt cells that 
were similar microscopically in location and morphology with Paneth cells. While 
Paneth cells are a logical source for SBD-2, the presence of stained cells (including 
goblet cells) at the base of jejunal and ileal villi along with stained cells in the colon 
and rectum suggests other epithelial cells may be involved. In our study, goblet cells 
low on the villus were immunoreactive while more mature goblets cells higher on the 
villus lacked staining. This is consistent with an electron microscopy study showing 
a-defensin positive granules in immature murine goblet cells but not in mature goblet 
cells of the upper half of the villus [14]. Immature goblet cells may represent a 
cellular source for moderate SBD-2 expression that is widely situated throughout the 
intestines. We also show that SBD-2 mRNA levels decrease caudally from the 
jejunum to the rectum in adult sheep (p=0.008) and for combined age group (0.052). 
Similarly, the immunoreactivity was highest in the jejunum with progressive decrease 
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caudally to the rectum. The decreasing expression from jejunum to rectum could 
partially be explained by the relative tissue distribution of Paneth cells. 
The consistent expression of SBD-2 mRNA in the intestine may reflect an 
emerging role for beta-defensins in adaptive immunity. Human beta-defensins-1 &-2 
are ligands for CC-chemokine receptor-6 (CCR6), a surface receptor of CD45RO+ 
memory T cells and bone-marrow derived immature dendritic cells [14,15,16]. 
Altered expression of CCR6 ligand can regulate the trafficking of these cells to the 
intestines [17,18]. While interactions between SBD-2 peptide and surface receptors 
have not been performed, SBD-2 may have similar activity and serve as a human 
model for investigations of beta-defensin innate and adaptive immune regulation. 
An additional observation was the absence of immunoreactivity by the ileal 
FAE. Peyer"s patches and FAE of the sheep ileum are most pronounced in the 
young animal and by adulthood are significantly regressed [19]. The FAE in the 
ruminant ileum is composed of a nearly uniform, specialized cell population that 
resides over lymphoid tissue (e.g. Peyer"s patch) on discrete dome villi [20]. These 
specialized epithelial cells have surface folds that can internalize particulate matter 
for lysosomal degradation with subsequent exocytosis of the residual bodies [21]. In 
some species, the FAE has reduced protective mechanisms (glycocalyx and mucus 
layer) as compared to absorptive epithelium that can facilitate interaction with 
microbes for antigen sampling [22, 23, 24]. The lack of antimicrobial peptides such 
as SBD-2 in cells of the FAE may facilitate intimate access by microbes for antigen 
sampling. 
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Extra intestinal SBD-2 mRNA was inconsistently and weakly expressed by a 
wide range of tissues. While SBD-2 mRNA was detected in extra-intestinal tissues 
by real time PGR, the peptide production was insufficient for detection by 
immunohistochemistry. The young lambs (combined fetus/neonate) had a 
significantly wider tissue distribution of SBD-2 mRNA than the adult group. To our 
knowledge we are the first to report a wider defensin tissue distribution in developing 
individuals compared to mature ones. While beta-defensins are increasingly known 
for their role in mucosal immunity, beta-defensins have also been shown to 
participate in cellular differentiation/growth /n vAm [11,25]. A role in cellular 
growth/differentiation may explain the wider SBD-2 tissue distribution in young 
developing animals. 
This study shows SBD-2 expression and distribution in the fetus, neonate and 
adult sheep. This provides a foundation for future efforts to examine the inducibility 
and role of SBD-2 in specific tissues and diseases. 
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Jejunum Ileum Sp. Colon Rectum 
Jejunum Ileum Sp. Colon Rectum 
FIG. 1. SBD-2 mRNA levels in intestine relative to calibrator tissue. (A) Intestinal expression 
in adult sheep. (B) Intestinal expression in neonatal lambs. (C) Intestinal expression in 
preterm lambs (fetus). 
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FIG. 2. Immunohistochemical detection of SBD-2 peptide in the jejunal crypts of 
adult sheep. Approximately half of the cells are immunoreactive for SBD-2 peptide, 
Bar = 50 microns. 
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FIG. 3. Immunohistochemical detection of SBD-2 peptide in ileum of neonatal lamb, 
the absorptive epithelium (arrows) has multiple immunoreactive cells (including 
goblet cells) while the follicle-associated epithelium (arrowheads) lacks 
immunoreactivity, Bar = 50 microns. 
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Table 1. SBD-2 mRNA* distribution in selected tissues of 
fetus, neonatal and adult sheep (n = 3/group). 
Fetus Neonate Adult" 
Jejunum 3C 3 3 
Ileum 3 3 3 
Spiral colon 3 3 3 
Rectum 3 3 3 
Trachea 2 1 0 
Kidney 2 1 0 
Turbinate 1 0 0 
Urinary bladder 1 2 0 
Lung 1 1 0 
Liver 1 0 0 
Uterus - - 1 
a Tissues were considered positive by real-time PGR if SBD-2 
mRNA was amplified within 45 cycles. 
b SBD-2 mRNA tissue distribution in the adult group was 
significantly less than those in the fetus/neonate groups combined 
(p=0.04). 
' Represents die number of tissues (0 to 3) with amplified SBD-2 
mRNA from each group. 
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CHAPTER 4. ADENOVIRUS-MEDIATED GENE THERAPY ENHANCES 
PARAINFLUENZA VIRUS-3 INFECTION IN NEONATAL LAMBS 
A paper submitted to the Jouma/ of CWca/ M/cmb/o/ogy 
David K. Meyerholz, Branka Grubor, Jack M. Gallup, Howard D. Lehmkuhl, Richard 
D. Anderson, Tatjana Lazic and Mark R. Ackermann 
Abstract 
Parainfluenza viruses are a common cause of seasonal respiratory disease, 
but in high-risk individuals (e.g. young children) these viruses can cause severe 
clinical manifestations that require hospitalization. Beta-defensins are a subclass of 
antimicrobial peptides with antiviral activity. Use of adenoviral-mediated beta-
defensin gene expression has been proposed as therapy for chronic bacterial 
infection commonly seen in cystic fibrosis patients; however, its use during 
parainfluenza virus-3 (PIV3) infection has not been evaluated. The hypothesis of this 
experiment was that adenoviral expression of human beta-defensin-G (HBD6) would 
diminish concurrent PIV3 infection in neonatal lambs. The PIV3/Ad/HBD6 group had 
increased recruitment of pulmonary neutrophils compared to the PIV3 or PIV3/Ad 
groups with increased respiration rate and body temperature late in the course of the 
PIV3/Ad/HBD6 infection. Interestingly, the adenovirus treated groups had higher 
PIV3 immunohistochemical staining and syncytial cell formation than did the PIV3 
group suggesting that treatment with the adenovirus vector, regardless if carrying a 
target gene, exacerbated the PIV3 infection. The mRNA of antimicrobial surfactant 
proteins A&D and sheep beta-defensin-1 were increased by PIV3 and adenoviral 
treatment, roughly corresponding to the degree of inflammation. While high dose 
pulmonary administration of an adenovirus vector has been associated with 
undesirable inflammation, this is the first study to show that it can exacerbate 
concurrent viral infection, a concern that needs to be addressed for future adenoviral 
studies in the lung. Additionally this study showed that adenoviral-mediated HBD6 
expression increases neutrophil recruitment, a recently described attribute of beta-
defensins, with mild accentuation of PIV3 activity and inflammation. 
Introduction 
Parainfluenza viruses-1 and -3 are enveloped, single-strand, negative-sense 
RNA viruses of the Paramyxoviridae family and are an important, ubiquitous cause 
of seasonal respiratory disease. Infection in a healthy individual is localized primarily 
to the upper respiratory tract and is often self-limiting (13, 27). However, human 
parainfluenza viruses can cause more serious respiratory disease such as severe 
laryngotracheitis ("croupy" cough), bronchiolitis and pneumonia leading to 
hospitalization and on rare occasions, death (15). Risk factors for severe 
manifestations of parainfluenza virus infection include: primarily lung disease (e.g. 
cystic fibrosis or asthma), the immunocompromised (e.g. transplant recipients), 
young children, and the elderly (9,15,16). Parainfluenza viruses, along with other 
viruses are increasingly recognized in exacerbation of cystic fibrosis lung disease 
and may predispose to secondary bacterial infection, including Pseudomonas 
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aemg/nosa which is a persistent problem in cystic fibrosis lungs (37). Young children 
and infants with cystic fibrosis are at increased risk for lower respiratory tract 
infections by these ubiquitous viruses resulting in increased hospitalization rates and 
chronic lung damage (16, 36). 
Defensins are a conserved class of antimicrobial peptides characterized by a 
cationic charge, antimicrobial activity and six to eight highly conserved cysteine 
residues that form intramolecular disulfide bonds. There are three families of 
defensins including alpha-, beta- and theta-defensins each characterized by the 
organization of intramolecular disulfide bonds (39). Beta-defensins are a class of 
cationic antimicrobial peptides that are produced primarily in epithelium at mucosal 
sites including the lungs (30). There are over thirty putative human beta-defensin 
genes and many of those gene products already characterized have a wide 
spectrum of microbicidal activity against bacteria, fungi and enveloped viruses (1, 
31). Antiviral action by beta-defensins is thought to be through disruption of the viral 
envelope, however recent work in alpha-defensins suggests the antiviral activity may 
also involve intracellular cell signaling to inhibit viral replication (6, 30). Inactivation of 
beta-defensins by the altered local environment (e.g. altered salinity or airway 
surface liquid) has been suggested to contribute to the increased susceptibility of 
cystic fibrosis patients to pulmonary infection (3,11). 
Perinatal lambs are commonly used models for pulmonary disease research 
including those involving gene therapies (19, 26). Perinatal lambs are susceptible to 
ovine isolates of PIV3, which have similar genomic and antigenic properties to 
human PIV3 and causes spontaneous respiratory disease and lesions in sheep (20, 
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33). Previous work in the human bronchial xenograft model using adenoviral 
mediated gene therapy with over-expression of a cathelicidin antimicrobial peptide 
(LL-37/hCAP-18) showed success in killing bacteria suggesting a use for 
antimicrobial gene therapy in predisposed patients (4); however, evaluation of 
antimicrobial peptide gene therapy has not been applied to diminish viral infection. 
Human beta-defensin-6 (HBD6), a recently described beta-defensin selectively 
expressed in the epididymis, was chosen as the antimicrobial peptide in this model 
due to its lack of expression in the human lung or in sheep (38). The hypothesis of 
this study was that HBD6 gene expression in the neonatal lamb lung would diminish 
concurrent PIV3 infection in neonatal lambs. 
Materials and methods 
Animals 
All animal studies were approved by the Iowa State University Animal Care 
and Use Committee. Neonatal lambs (n=20) were obtained from Iowa State 
University's Laboratory Animal Resources. At 3-5 days after birth (allowing time for 
acclimation) the lambs were inoculated intratracheal^  with two, twenty milliliter 
volumes at approximately thirty minute intervals. The order and composition of the 
inoculum for each group (n=4) were as follows: Group A) sterile media/sterile media, 
(Control group); B) sterile media/PIV-3, (PIV3 group); C) adenovirus vector (no gene 
insertion)/PIV-3, (PIV3/Ad group); or D) adenovirus-HBD6/PIV-3, (PIV3/Ad/HBD6 
group). At day seven of infection the lambs were euthanized by an intravenous 
injection of sodium pentobarbital for collection of tissues. This time point was chosen 
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from our preliminary data as the time of significant lesion development and active 
viral clearance. An additional group of lambs were given an intratracheal inoculation 
(20 ml) of sterile media (n=2) or an adenovirus/HBDG (n=2) also containing a /acZ 
gene insert for cellular localization of transfection. These lambs were euthanized at 
day 4 of infection which is near the peak for pulmonary adenoviral vector gene 
expression (10). 
Viruses 
The ovine isolate of parainfluenza-3 virus was grown as previously described 
to 107 8 TCIDso/ml (20 ml per lamb) (20). The replication defective human 
adenovirus-5 vector (Ad) had a cytomegalovirus promoter and was commercially 
acquired with the human beta-densin-6 (HBD6) gene (IMAGE consortium ID # 
2602699), HBD6 with a /acZ reporter gene, or no gene insert (ViraQuest Inc., North 
Liberty, Iowa). The Ad (no gene insert) and Ad/HBD6 had an E1 deletion 
(nucleotides 358 to 3328) and the Ad/HBD6/LacZ insert for X-gal staining had 
deletions at nucleotides 358 to 3328 and 28592 to 30470 with concurrent loss of 
E1/E3 functions. Each lamb received approximately 10  ^virus particles in 20 ml of 
sterile saline. 
Clinical parameters 
The lambs were assessed daily for different clinical parameters. Body weight, 
temperature, and respiratory rate were taken at the same time of day following the 
morning feeding. The lambs were treated daily with antibiotic (ceftiofur 10 mg/day, 
SQ) to prevent complications associated with secondary bacterial infection (34). 
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Tissues 
Lung tissue was collected consistently from the cranial and caudal lobes on 
the left and right sides. Tissues were placed in 10% neutral-buffered formalin and 
processed routinely for hematoxylin and eosin staining or immunohistochemistry. In 
addition, lung tissue was snap frozen in liquid nitrogen for RNA isolation and real 
time fluorogenic PGR. 
Ribonucleic acid isolation 
Ribonucleic acid isolation and complementary deoxyribonucleic acid 
production were performed as previously described (24). Briefly, 0.3 g of tissue and 
3 ml of Thzol reagent (Invitrogen) were homogenized for 30 seconds and the 
homogenate was allowed to sit for five minutes at room temperature. Chloroform 
(0.6 ml) was added and the mixture was shaken vigorously for fifteen seconds then 
allowed to sit for three minutes at room temperature. This mixture was microfuged 
for ten minutes at 4° C, and the resulting top aqueous layer was retrieved and mixed 
with isopropanol (1.5 ml) and allowed to sit for ten minutes at room temperature. The 
solution was again microfuged for ten minutes at 4° C, the aqueous/isopropanol 
layer removed and the visible pellet resolubilized in nuclease-free HPLC-grade water 
containing 0.1 mM EDTA. Spectrophotometer measurements were then taken of 
each RNA isolate (detection at 260nm and 280nm absorbances of 1:40 sample 
dilutions) to assess the isolates for purity and quantity. 
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Complementary deoxyribonucleic acid production 
RNA samples were treated with a commercially available deoxyribonuclease 
(DNase) (RQ1 RNase-Free DNase, Promega) to remove potential genomic 
deoxyribonucleic acid (DNA) contamination. Immediately after this, reverse 
transcription was performed with a commercially available kit (TaqMan Reverse 
Transcriptase Reagents, PE Biosystems) following manufacturer's directions. Briefly, 
2 |ig of DNase-treated RNA from each sample and control were added to a reaction 
mixture which contained final concentrations of 1X TaqMan RT buffer, 5.5 mM 
MgCb, 2 mM deoxyribonucleoside triphosphate (dNTP) mixture (500 each 
dNTP), 2.5 random hexamers, 1.25 U/|il murine leukemia virus (MuLV) RT, 0.4-
0.8 U/|il ribonuclease (RNase) inhibitor and HPLC-grade water. The following 
thermocycler conditions were then used: 10 minutes @ 25° C, 30 minutes @ 48° C 
and 5 minutes @ 95° C. Resulting cDNA was stored in nuclease-free 
microcentrifuge tubes at 20° C. 
Primer and Probe Design 
Sequence-specific oligonucleotide primers and a fluorescent probe were 
designed with software (ABI Prism Primer Express, Version 1.5, PE Applied 
Biosystems) according to the software manufacturer's suggestions. Resultant 
potential primer and probe sequences were compared to all available DNA 
sequence databases via the search tool BLAST (Basic Local Alignment Search Tool, 
Version 1.4, National Center for Biotechnology Information) for similarity, and only 
unique sequences were used for primer and probe design (Table 1). Sequence-
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specific oligonucleotide primers and a fluorescent probe for detection of cDNA 
corresponding to the endogenous reference gene, 18S Ribosomal RNA, to which 
target cDNA levels would be normalized, were purchased commercially (TaqMan 
Ribosomal RNA Control Reagents, PE Biosystems). 
Polymerase Chain Reaction 
The 96-microwell plates were designed to enable two replicates for both the 
target gene and endogenous 18S ribosomal RNA of: 1:5 dilution cDNA from all 
lambs, negative control (DEPC-treated water), and five progressive 1:5 dilutions of 
cDNA from a control sheep for generation of the standard curve. On each plate, 
target and endogenous reference PCR wells were run simultaneously for the tissues 
represented on that plate. The plate was run in the sequence detection system 
(GeneAmp 5700 Sequence Detection System, Version 1.3, Applied Biosystems) 
with conditions identical to those used in the optimization and validation tests. 
Resultant data gathered by the detection system was exported from the machine to 
floppy disk, and all final data processing was performed using a departmentally-
designed EXCEL file to compare target to reference cDNA signals in order to create 
relative mRNA expression graphs. 
Parainfluenza virus-3 immunohistochemistry 
Formalin-fixed, paraffin embedded sections were deparaffinized in xylene 
followed by a series of alcohol baths and Pronase E (0.1 g Protease XIV and 0.1 g 
CaCb per 100 mL TBS pH 7.4) was applied for antigen retrieval. After washing 
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(PBS), the background blocker (20% normal swine serum) followed by primary 
antibody (goat polyclonal anti-bovine parainfluenza virus-3,1:1000, [VMRD]) was 
applied to the tissues. These were washed, hydrogen peroxide (3% in methanol) 
applied to block endogenous peroxidases and washed again. Secondary antibody 
(1:400 biotinylated rabbit anti-goat) was applied followed by washing, SS-HRP and 
chromogen (Vector Red, Vector). The slides were counterstained with hematoxylin, 
dehydrates in a series of alcohol baths then xylene and cover slipped with 
Permount. 
Morphometry 
Measurement of microscopic morphological changes including cellular 
staining, mitotic rate, neutrophil density, and syncytial cell formation were assessed 
by a pathologist blinded from the study using a grid (19). Cranial and caudal lung 
lobes (bilaterally) were used for the study. For each slide, the pathologist randomly 
chose ten sites from low power, then the selected morphological alteration was 
counted at high power. This was done for each segment of lung, the results were 
totaled and averaged to the grid area (13,000 or 52,000 |im^). 
Adenovirus distribution 
OCT embedded frozen sections were cut at 6 p,m and placed in a bath of 4% 
formaldehyde for 5 minutes and the slides were then washed twice in HBSS. X-gal 
staining solution (20 mg [5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside] per 
ml of N'N'-Dimethylfonnamide) was added (20 l^/ml) to a fresh solution of 5mM 
116 
potassium ferricyanide, 5mM potassium ferrocyanide, 2 mM magnesium chloride in 
HBSS for the final X-gal working solution. Slides were then exposed to the final X-
gal working solution for 10 hours at 37°C. The slides were washed in HBSS counter 
stained with nuclear fast red and cover slipped. Sections were then examined for 
cells staining blue indicative of LacZ expression (24). 
Statistics 
For assessment of clinical and fluorogenic real-time PGR data, significance 
was determined to be p<0.05. Non-parametric Wilcoxon tests were used to assess 
for statistical differences in unequal sized samples. T-tests assuming unequal 
variances were used to assess for differences in the means of groups of equal size. 
Results 
The daily body temperatures showed early and late increases through the 
course of infection. On day two, body temperatures for all PIV3 infected groups were 
generally increased with the PIV3/Ad/HBD6 having a significantly higher 
temperature than the control (p<0.01, Figure 1). Starting on day five the 
PIV3/Ad/HBD6 group had significantly increased body temperature over controls 
that continued through the duration of the experiment (p<0.05). The PIV3 and 
PIV3/Ad had moderately increased temperatures that were not statistically 
significant except for the PIV3 group on day 6 (p<0.01). 
The respiration rate on day two was significantly higher in the PIV3/Ad group 
(p<0.05) and moderately elevated in the PIV3/Ad/HBD6 group (p=0.08) compared to 
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the PIV3 group (Figure 2). By day four through the course of infection the PIV3 
infected groups were generally elevated (p<0.05) above the controls, except for an 
increase that lacked statistical significance for the PIV3/Ad/HBD6 group on day 6. 
Interestingly, the PIV3/Ad/HBD6 group had a slightly higher respiration rate on day 
six and seven than did the PIV3 or PIV3/Ad group. 
Daily milk consumption (liters per kilogram body weight) was evaluated to 
determine if there were any clinical differences in appetite. For the duration of the 
experiment the PIV3, PIV3/Ad, and PIV3/Ad/HBD6 groups had decreased (p<0.05) 
average milk consumption compared to the control group with no significant 
difference among the PIV3 treated groups (Figure 3). 
Growth of the lambs (average daily gain, kg/day) during the experiment 
corresponded to the milk consumption with significantly decreased growth in the 
PIV3 (p<0.05) and PIV3/Ad/HBD6 (p<0.05) groups (Figure 4). The PIV3/Ad showed 
a similar decrease in growth but was not statistically significant. 
Grossly, the control lambs had no visible lesions while the PIV3, PIV3/Ad and 
PIV3/Ad/HBD6 groups had a cranial-ventral to hilar distribution of multifocal plumb-
red consolidation. There was a slightly wider lesion distribution in the PIV3/Ad and 
PIV3/Ad/HBD6 groups over the PIV3 group. Microscopically the PIV3 lesions 
consisted of multifocal thickening of the alveolar septa by macrophages, and a small 
number of lymphocytes, neutrophils and plasma cells. The bronchiolar lumens 
contained small aggregates of neutrophils and sloughed cellular debris. Within these 
areas, the bronchiolar epithelium was thickened due to hyperplasia with folds of 
piled cells having pale cytoplasm, increased mitotic figures and infrequent syncytial 
118 
cells. The PIV/3/Ad/HBD6 group appeared to have relatively higher numbers of 
neutrophils within lung when compared to lambs inoculated with PIV3 alone. 
To evaluate neutrophil recruitment to the lungs following treatment, 
pulmonary neutrophil density was determined by morphometry. There was a 
significantly increased neutrophilic infiltrate in each of the PIV3 infected groups over 
the sterile media controls (p<0.05, Figure 5). In addition, the PIV3/Ad/HBD6 group 
had a higher neutrophil count than did either of the PIV3 or PIV3/Ad groups 
(p<0.05). 
PIV3 immunohistochemistry produced no staining in the control lungs while 
cellular staining was present in all lambs of the PIV3 infected groups. This was 
characterized by small granular red staining within the cytoplasm (Figure 6). Affected 
cells most often were epithelial cells of the distal bronchi to terminal bronchioles. 
Morphometrical quantification of the cellular PIV3 immunostaining showed increased 
immunoreactive cells in PIV3/Ad (p<0.05) and PIV3/Ad/HBD6 (p<0.05) groups 
compared to the PIV3 group (Figure 7). 
The mitotic rate was significantly increased in all of the PIV3 infected groups 
over the control group (Figure 8). No significant changes within the PIV3 infected 
groups were evident. PIV3-induced syncytial cell formation was not present in the 
control group but was present in all of the PIV3 infected groups. The combined 
adenoviral gene therapy groups had higher syncytial cell density than did the PIV3 
infected lambs (p<0.05, Figure 9). 
The adenovirus vector was localized by X-gal staining to a small number 
(<5%) of individual epithelial cells of the bronchi and terminal bronchioles (data not 
119 
shown). This staining was not seen in samples from two control lambs inoculated 
with sterile media. 
Real-time fluorogenic polymerase chain reaction was used to assess for 
transfection of HBD6 and for alterations in host mRNA of SBD1, SP-A and SP-D. 
For HBD6, the control (PIV3/Ad inoculated) groups had no fluorogenic amplification, 
while all four of the HBD6 inoculated lambs had late-cycle amplification indicating 
weak HBD6 expression (data not shown). Expression of SP-D in each PIV3 infected 
group was significantly elevated over the control group and the expression levels 
tended to increase from the PIV3/Ad group to the PIV3/Ad/HBD6 group (Figure 10). 
Similar trends were present in the SP-A and SBD1 mRNA expression with statistical 
significant seen in the combined PIV3/Ad and PIV3/Ad/HBD6 groups versus the 
PIV3 group for both SP-A and SBD1 (p<0.05, Figures 11 and 12). 
Discussion 
The hypothesis of this study was that beta-defensin (HBD6) expression 
during concurrent PIV3 infection would diminish the disease progression. Clinical 
parameters were monitored during the course of infection and day seven of infection 
was chosen for necropsy as lesions are usually marked with active viral clearance in 
lambs (7, 20). All PIV3 infected groups had clinical evidence of infection (e.g. 
elevated temperature and tachypnea, depresses milk consumption and growth); 
gross and microscopic lesions consistent with PIV3; and immunohistochemical 
staining in PIV3-infected animals only. Adenovirus transfection was confirmed with 
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X-gal staining in Ad/HBDG/LacZ infected ainway epithelium on day four and by HBD6 
mRNA expression on day seven of infection. 
The adenovirus treated groups (PIV3/Ad and PIV3/Ad/HBD6) had increased 
temperatures and respiration rates on day two of infection. This was consistent with 
previous work in which BALB/c mice showed increased proinflammatory cytokines of 
tumor necrosis factor-alpha (TNF-alpha) and interleukin-G (IL-6) within even hours of 
human adenovirus 5 intrapulmonary inoculation, (40). TNF-alpha and IL-6 are 
endogenous pyrogens accounting for the increased temperature and TNF-alpha 
mediates bronchial and vascular smooth muscle contractility which along with 
pyrexia could have increased the respiratory rate (2, 35). Other clinical alterations 
compared to the controls were generally attributable to PIV3 infection. Of particular 
interest was that the adenoviral treated groups had increased PIV3 staining and 
syncytial cell formation than did the PIV3 groups lacking adenoviral treatment. 
Antigen staining occurs at sites of PIV3 protein synthesis and syncytial cell formation 
is mediated by the fusion (F) protein with regulation by the hemagglutinin-
neuraminidase (HN) protein, both indicators are byproducts of PIV3 replication (28). 
The increased immunostaining and syncytial cell formation were both 
indicative of enhanced PIV3 viral activity (21, 28). This novel finding suggests that 
pulmonary adenoviral mediated gene therapy can exacerbate concurrent PIV3 
infection. Proteins of adenoviruses, including E1A, E1B and E3 proteins, have been 
shown to have immunomodulating functions most of which are immunosuppressing 
(17, 29). The vector used in this study had an E1 deletion with the E3 gene intact. 
E3 gene products inhibit: peptide processing for MHC I presentation; activation of 
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nuclear factor-kappaB (NF-icB); and apoptosis through FAS, TRAIL and TNF-alpha 
pathways (5, 8,17, 29, 32). MHC I processing and apoptosis of virus infected cells 
are important mechanisms for viral clearance and the synthesis of antiviral type I 
interferon along with other inflammatory mediators are mediated in part through NF-
%B activation. Early E3 inhibition of antiviral pathways could have allowed for more 
enhanced PIV3 replication and infection. While immunosuppressive effects of 
adenovirus E3 gene may participate in enhancing PIV3 infection, the small cellular 
distribution of the adenovirus suggests this may not be a significant component. 
Another mechanism for the enhanced PIV3 infection may be the general 
inflammatory and cellular changes caused by the addition of the adenovirus vector. 
In previous work, pretreatment of 4-ipomeanol similarly enhanced PIV3 activity in a 
calf model (21). The 4-ipomeanol compound is biotransformed in Clara cells into a 
free radical metabolite which causes necrotizing bronchiolitis and interstitial 
pneumonia. The authors of the PIV3 calf model hypothesized that 4-impomeanol 
may 1) suppress pulmonary innate defenses; 2) increase the number of susceptible 
cells; or 3) increase factors (e.g. proteases) for enhanced viral replication. Early 
immunosuppression by adenoviral proteins and/or altered cellular susceptibility to 
PIV3 infection/replication may contribute to this increased PIV3 activity in adenovirus 
treated lambs. Further work needs to clarify and define the mechanism. 
We further evaluated the mRNA levels of innate antimicrobial peptides and 
proteins to determine if adenoviral gene therapy altered mRNA expression. SP-D 
was increased for each PIV3 group over the control group (p<0.05) with moderate 
increases in the PIV3/Ad/HBD6 group over the PIV3/Ad and PIV3 groups. Similar 
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trends were seen for SP-A and SBD1 with significant increases in the combined 
PIV3/Ad and PIV3/Ad/HBD6 group over the PIV3 groups (p<0.05). Surfactant protein 
and beta-defensin mRNA expression is partially regulated by the status of 
pulmonary inflammation and lung injury (22, 30). The increases seen here are likely 
a coordinated response to exacerbated inflammation and injury associated with 
inoculation of adenoviral vector and exacerbated PIV3 viral infection. 
The effect of m two HBD6 expression on PIV3 infection was unanticipated as 
it tended to be proinflammatory, aggravating to the overall clinical situation. 
Microscopically, neutrophil infiltration was increased in the PIV3/Ad/HBD6 group and 
this was confirmed with morphometry in which the neutrophils density was increased 
(p<0.05) over either PIV3 or PIV3/Ad groups. Clinical scores of body temperature 
and respiration rates for PIV3/Ad/HBD6 groups were increased over control with 
slight increases over the PIV3/Ad group. Beta-defensins, while increasingly known 
for their antimicrobial properties, have additional functions such as leukocyte 
chemotaxis and immunomodulation (30). Recently, HBD2 was shown to function /n 
vffm as a chemoattractant for TNF-alpha primed neutrophils and HBD2 ligand 
interaction with CC-chemokine-receptor-6 (CCR6) was considered the mechanism 
for chemotaxis (25). TNF-alpha expression is an early consequence of pulmonary 
adenovirus mediated gene therapy and may prime the neutrophils for CCR6 
mediated chemotaxis (40). The HBD6 expression in these lambs stimulated both 
increased neutrophilic infiltrate and accentuated clinical parameters of PIV3 disease 
without decreasing PIV3 activity, but rather accentuating it. Although HBD6 
expression is the likely source for these events, specific interaction between 
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adenovirus vector and HBD6 expression cannot be ruled out. While HBD6 efficacy 
against pathogenic organisms has not been established, this study did show the first 
m y/yo recruitment of neutrophils by beta-defensin expression and that HBD6 
expression during gene therapy has biological activity in the neonatal lamb lung. 
Adenovirus mediated gene therapy in the lung has been hindered by the 
inflammatory response it generates. In this study a high concentration of adenovirus 
(23, 26) was used fortransfection, which accentuated PIV3 activity. Recent 
technological advances such as pretreatment of airways with sodium caprate or 
complexing the adenovirus with DEAE dextran have been used to provide means of 
reducing the adenoviral titer required and thus minimizing the adverse effects (12). 
Another limitation of this study is the small number of lambs used in each group, a 
common problem associated with large animal work, which sometimes makes 
statistical significance challenging due to inter animal variations (24). However, large 
animal studies (as in this case) can provide novel insights to disease mechanisms 
not readily observed in rodent or other laboratory animal models (14). In this study 
we used an ovine isolate of PIV3 virus for the neonatal lamb study which is 
comparable to human PIV3 in disease and lesions (7,15, 20). This is the first study 
to show high dose adenoviral gene therapy may exacerbate a concurrent PIV3 
infection, a concern that needs to be further addressed for future adenovirus gene 
therapy. Additionally, this is the first study to show /n y/yo HBD6 expression has 
biological activity, specifically in neutrophil recruitment with mild aggravation of 
concurrent PIV3 infection. 
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Figures 
Figure 1. Body temperature 
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Figure 1. Body temperature for the treatment groups. The PIV3 group had 
significantly increased temperatures over the control group on day 6 while the 
PIV3/Ad/HBD6 group had increased temperatures over controls on days 2, 5, 6 and 
7, (*p<0.01 or **p<0.05 versus control). 
Figure 2. Respiration rate 
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Figure 2. Respiration rate for treatment groups. On day 2 the PIV3/Ad group and the 
PIV3/Ad/HBD6 groups (p=0.08) had increased respiration rate compared to the PIV3 
group. Starting at day 4 the PIV3 infected groups had increased respiration rates 
over controls with the PIV3/Ad/HBD6 group being slightly higher on days 6 and 7, 
(*p<0.05 versus control; **p<0.05 versus PIV3 group). 
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Figure 3. Milk consumption 
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Figure 3. Daily milk consumption for the treatment groups. The PIV3 infected groups 
all had similar decreases in milk consumption, (*p<0.05 versus control). 
Figure 4. Lamb growth 
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Figure 4. Average daily gain for the treatment groups. The PIV3 and PIV3/Ad/HBD6 
groups had a significant decrease in growth while the PIV3/Ad group had a slightly 
decreased growth rate compared to controls, (*p<0.05 versus control). 
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Figure 5. Pulmonary neutrophil 
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Figure 5. Pulmonary neutrophil density in the treatment groups. All the PIV3 infected 
groups had higher neutrophil density than did the control group. The PIV3/Ad/HBD6 
group had increased neutrophil density over PIV3 and PIV3/Ad groups, (*p<0.05 
versus control; **p<0.05 versus PIV3 or PIV3/Ad groups). 
A. 
135 
B. 
G ? . I -  ^  M  ^ 3 K I # i  
c. 
Figure 6. Immunohistochemistry for PIV3 in the A) PIV3 group, B) PIV3/Ad group and C) 
PIV3/Ad/HBD6 group, (all 400x magnification). The PIV3/Ad and PIV3/Ad/HBD6 groups had 
increased cellular staining over the PIV3 group. The control group had no staining (not 
shown). 
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Figure 7. Cellular PIV3 antigen staining density 
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Figure 7. Cellular PIV3 antigen staining in treatment groups. PIV3/Ad and 
PIV3/Ad/HBD6 groups each had significant increases in PIV3 antigen staining over 
the PIV3 group. The control group had no staining, (*p<0.05 versus PIV3 group). 
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Figure 8. Mitotic rate in the treatment groups. PIV3, PIV3/Ad and PIV3/Ad/HBD6 
groups had similar significant increases in mitotic rate over the control group with no 
significant differences among the PIV3 infected groups, (*p<0.05 versus control 
group). 
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Figure 9. Syncytial cell formation 
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Figure 9. Syncytia cell formation in the treatment groups. The combined PIV3/Ad 
and PIV3/Ad/HBD6 had significantly higher syncytia cell formation than did the PIV3 
group, (*p<0.05 versus PIV3 group). 
Figure 10. SP-D mRNA expression in neonatal 
lambs 
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Figure 10. SP-D mRNA expression in the treatment groups. PIV3. PIV3/Ad and 
PIV3/Ad/HBD6 groups are all increased compared to the control group with 
moderate increase in the PIV3/Ad/HBD6 group over the PIV3/Ad group, (*p<0.05 
versus control group). 
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Figure 11. SP-Â mRNA expression in neonatal 
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Figure 11. SP-A mRNA expression in the treatment groups. The combined PIV3/Ad 
and PIV3/Ad/HBD6 groups had significantly increased SP-A mRNA compared to the 
PIV3 group, (*p<0.05 versus PIV3 group). 
Figue 12. SBOl mRNA expression in neonatal 
lambs 
Control RV3 PIVS/Ad PIV/Ad/HBDS 
Group 
Figure 12. SBD1 mRNA expression in the treatment groups. The combined PIV3/Ad 
and PIV3/Ad/HBD6 groups had significantly increased SBD1 mRNA compared to 
the PIV3 group, (*p<0.05 versus PIV3 group). 
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CHAPTER 5. GENERAL CONCLUSION 
Death in preterm infants is often attributed to respiratory disease and this 
same age group is at increased risk for severe Paramyxoviral disease (2,18). 
Because the respiratory epithelia are not fully developed at this time, suboptimal 
expression of innate immune factors, in part, is thought to predispose high risk 
groups to infection (5,12, 24). Supplementation of innate immune factor such as 
beta-defensins could augment the status of innate pulmonary immunity. The 
preterm/perinatal lamb is a viable model for the study of Paramyxoviral infection, 
beta-defensin expression, and adenoviral gene therapy. This work 1) characterizes 
RSV infection in the preterm lamb model, 2) defines the developmental distribution 
and expression of SBD2 and 3) describes the influence HBD6 expression by 
adenoviral mediated gene therapy on the clinicopathological features of PIV3 
infection. 
RSV In the Preterm Lamb Model 
There is currently no distinct RSV animal model which can be used to study 
the predisposition to age-dependent disease severity seen in preterm infants. Work 
in this dissertation demonstrates that preterm lambs are susceptible to bovine RSV 
infection and is a recognized viral model that parallels human RSV infection (9,11). 
Infected lambs exhibited clinical signs and lesions comparable with that of human 
RSV disease. The clinical features were similar to or slightly less severe than that of 
human infection and the gross and microscopic lesions were consistent to that 
described for severe infection in preterm infants (8). The preterm lamb RSV model 
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has several advantages compared to other RSV models (e.g. rodents) including 
similar lung development and susceptibility to natural RSV infection (11,16). 
In addition, preterm RSV infection was compared to neonatal lambs given 
similar or three-logarithm higher TCID# inoculum. The cellular antigen staining and 
syncytial cell formation were both significantly increased in the pretenn group. This 
suggests that the preterm lambs were deficient in their ability to clear RSV infection 
compared to either group of neonatal lambs, even the one given a higher titer viral 
inoculum. 
This work demonstrated that preterm lambs are susceptible to RSV infection, 
a novel approach to using the full-term lamb model of RSV infection. More 
importantly, this work also showed reduced RSV clearance in preterm versus the 
full-term lambs with similar or high inoculum virus. Age-dependent RSV clearance in 
preterm lambs was similar to that seen in cotton rats used as a model of 
susceptibility to severe RSV infection in elderly humans (3). This inefficient RSV 
clearance is important as it can propagate detrimental airway inflammation and 
possibly be associated with RSV persistent infection or latency (15,17, 21). 
Sheep Beta-Defensin-2 Ontogeny 
A putative factor in the susceptibility of preterm infants to severe 
Paramyxoviral infection is the immature expression of the innate antimicrobial 
factors. In the sheep model, SBD2 has been suggested to have developmental 
regulation in the gastrointestinal tract, but the extent and distribution of this 
expression in the lung and other tissues was not previously defined (10). 
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Tissues were collected from late gestational fetuses, neonates, and adult 
sheep in order to define the tissue distribution and expression of SBD2. The SBD2 
mRNA and peptide were predominantly found in the gastrointestinal tract with 
highest expression in the jejunum and decreasing to the rectum. There was a 
progressive increase in the level of SBD2 expression in the gastrointestinal tissues 
with age reaffirming the concept of developmental regulation. SBD2 did not show 
consistent pulmonary expression in adult sheep. Preliminary work by others in our 
lab confirmed the lack of pulmonary expression and suggested SBD2 was not 
inducible in the lung. 
The SBD2 tissue distribution was wider in the developing younger animals 
compared to the mature adult sheep. This could suggest SBD2 has a developmental 
function in cellular proliferation or differentiation as has been described for other 
beta-defensins (1,4,14). 
Adenoviral Mediated Beta-Defensin Expression 
As mentioned above, there is a putative role of "immature" epithelial 
expression of beta-defensins as a predisposing factor for severe Paramyxoviral 
infection. A potential avenue for prophylactic or therapeutic intervention could 
include enhanced expression of a beta-defensin. Gene therapy would be an 
appropriate vehicle to accomplish this task since exogenous regulators of innate 
beta-defensin expression are not well-defined (20). HBD6 was selected as it was a 
recently described human beta-defensin with no concurrent expression in sheep and 
since it was available in an adenoviral vector. 
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In this study, m y/yo HBD6 expression caused significant increases in the 
pulmonary recruitment of neutrophils with slightly enhanced severity of 
clinicopathological parameters of infection. Instead of reducing PIV3 inflammation 
and disease, adenoviral-mediated HBD6 expression enhanced it. This study is the 
first to show /n y/yo biological activity of HBD6. Unexpectedly, this study suggests 
that enhanced expression of HBD6 is detrimental during PIV3 infection and would 
likely complicate the case management of affected patients rather than help them. 
The adenovirus vector and the unregulated HBD6 expression are possible 
contributing factors to the enhanced PIV3 severity in this study and need to be better 
defined before making judgment on the potential of beta-defensin therapy. 
As indicated, the use of adenovirus vectors, regardless of gene insert, was 
also detrimental to clinical and lesion parameters. Adenoviral vectors have been 
associated with inflammation, in part, due to the deletion of regions in the viral 
genome (e.g. E1) that are associated with host immunosuppression (19). 
Additionally, the high dose of adenovirus used in the study likely contributed to the 
enhanced inflammation (6). We were surprised to find that the presence of 
adenoviruses causes enhanced PIV3 activity in the neonatal lungs. This novel 
finding is significant as pulmonary adenoviral gene therapy research often involves 
subjects that are predisposed to Paramyxoviral infection. For example, in cystic 
fibrosis patients, concern over infection are mostly limited to bacteria such as 
Pseudomonas aeruginosa, but our works emphasizes that viral infection should also 
be a concern especially when performing adenoviral gene therapy. Our findings 
emphasize 1) the perinatal lamb as a viable PIV3 model providing novel insights to 
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pulmonary disease, 2) the importance of viral infection in these high risk individuals 
and 3) that gene therapy should warrant a high level of caution in its potential for this 
and other adverse effects. 
Recommendation for Future Efforts 
The preterm lamb model needs to be fully utilized for further efforts on 
Paramyxoviral infection given the novel age-dependent differences seen with RSV 
infection. For comparison, future work should include in addition to neonatal lambs, 
younger preterm lambs (~day 125-130) that require mechanical ventilation and 
preterm lambs (Caesarian-section - day 139) that are not infected until they are the 
same conceptional age as full term neonatal lambs. This would help define the 
developmental aspects of the susceptibility. Additional factors to evaluate in future 
work should include pulmonary function tests and antimicrobial peptide/protein 
expression (SP-A, SP-D, and SBD1). Also, I would highly recommend additional 
studies to further define the pathogenesis of bovine RSV by various inoculation 
routes and subsequent time course for lesion development. Having a well-defined 
RSV inoculation model with established replication and time courses for lesion 
development would be helpful for characterizing the potential value of novel 
prophylactic and therapeutic therapies. 
Concerning SBD2,1 think potential for pulmonary expression need to be 
further addressed /n wfm, specifically whether SBD2 expression is inducible. While 
preliminary efforts by others in our lab suggest it is not inducible, further /n Wfm 
efforts using various potential inducers (growth factors, cytokines, pathogen 
144 
products, etc.) to assure it is not a factor in pulmonary innate immunity. If in the end 
SBD2 does not show evidence of pulmonary involvement then beta-defensin 
pulmonary research can focus on SBD1 (7). Concerning SBD2's extra pulmonary 
involvement, I would suspect that its robust expression would provide a great model 
for inflammatory conditions of the intestines specifically Crohn's disease, Johne's 
disease, infectious diseases and inflammatory bowel disease (22, 23). There is great 
interest in the defensins of the gut related to these conditions, whether they are 
involved in the pathogenesis of the lesions or as possible therapeutic agents. 
Our work with the adenoviral vectors need to be further addressed, 
specifically, define the mechanism for the enhanced PIV3 disease associated with 
adenoviral mediated therapy. I would start by using an m Wfm culture model to try 
and rule out direct adenovirus and PIV3 interaction. This will likely need to be 
pursued /n wvo as I speculate the mechanism(s) are related to the enhanced 
inflammatory response thus either changing cellular signaling for the advantage of 
the virus or by enhancing exposure to additional viral entry sites (e.g. basolateral 
membrane). Additionally, future efforts with the adenovirus vector need to minimize 
the adenovirus-associated inflammation. One way this could be accomplished in the 
lung is by pretreatment with modifying agents (e.g. sodium caprate) to expose virus 
binding sites and enhanced transfection with a much smaller dose of vector (6). 
Another option would be to go to a third or fourth generation adenovirus vector which 
have decreased inflammatory responses compared with first or second generation 
vectors (13). This could decrease the adenovirus specific inflammatory response, an 
adverse consequence in the lung. 
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The enhanced neutrophilic recruitment along with clinical signs and 
inflammation seen with adenoviral mediated HBD6 expression are important 
concerns and may dampen the enthusiasm of some to beta-defensin therapy. 
However, the potential contributing factors such as the adenoviral-vector delivery 
mechanism and the unregulated expression of HBD6 need to be considered in 
future efforts to define the therapeutic potential of the beta-defensin for pulmonary 
use. The mechanism of the delivery (adenovirus vector) could be replaced by direct 
placement of a known amount of recombinant pro-peptide beta-defensin into the 
lung by tracheal instillation or nebulization. Additionally, as the regulation of epithelial 
differentiation and/or beta-defensin expression are further defined these potential 
compounds (e.g. retinoic acids, glucocorticoids, growth factors, etc.) could be used 
to up regulate expression. These could control the amount of beta-defensin 
expression in the lung and minimize the potential of harmful events. 
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